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A B S T R A C T
Background
Hepatocellular carcinoma (primary liver cancer) is classified in many ways. The Barcelona Clinic Liver Cancer (BCLC) group staging
classifies the cancer based on patient’s life expectancy. People with very early- or early-stage hepatocellular carcinoma have single tumour
or three tumours of maximum diameter of 3 cm or less, Child-Pugh status A to B, and performance status 0 (fully functional).
Management of hepatocellular carcinoma is uncertain.
Objectives
To assess the comparative benefits and harms of different interventions used in the treatment of early or very early hepatocellular
carcinoma through a network meta-analysis and to generate rankings of the available interventions according to their safety and efficacy.
However, it was not possible to assess whether the potential effect modifiers were similar across different comparisons. Therefore, we
did not perform the network meta-analysis and instead assessed the benefits and harms of different interventions versus each other or
versus sham or no intervention using standard Cochrane methodology.
Search methods
We searched CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, and trials registers to September 2016 to identify
randomised clinical trials (RCTs) on hepatocellular carcinoma.
Selection criteria
We included only RCTs, irrespective of language, blinding, or publication status, in participants with very early- or early-stage hepato-
cellular carcinoma, irrespective of the presence of cirrhosis, portal hypertension, aetiology of hepatocellular carcinoma, size and number
of the tumours, and future remnant liver volume. We excluded trials including participants who were previously liver transplanted. We
considered interventions compared with each other, sham, or no intervention.
Data collection and analysis
We calculated the odds ratio, mean difference, rate ratio, or hazard ratio with 95% confidence intervals using both fixed-effect and
random-effects models based on available-participant analysis with Review Manager 5. We assessed the risk of bias according to
Cochrane, controlled risk of random errors with Trial Sequential Analysis using Stata, and the quality of the evidence using GRADE.
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Main results
Eighteen trials met the inclusion criteria for this review. Four trials (593 participants; 574 participants included for one or more analyses)
compared surgery versus radiofrequency ablation in people with early hepatocellular carcinoma, eligible to undergo surgery. Fourteen
trials (2533 participants; 2494 participants included for various analyses) compared different non-surgical interventions in people with
early hepatocellular carcinoma, not eligible to undergo surgery. Overall, the quality of evidence was low or very low for all outcomes
for both comparisons.
Surgery versus radiofrequency ablation
The majority of participants had cirrhotic livers, and the hepatocellular carcinoma was of viral aetiology. The trials did not report the
participants’ portal hypertension status or whether they received adjuvant antiviral treatment or adjuvant immunotherapy. The average
follow-up ranged from 29 months to 42 months (3 trials).
There was no evidence of a difference in all-cause mortality at maximal follow-up for surgery versus radiofrequency ablation (hazard
ratio 0.80, 95% confidence interval (CI) 0.60 to 1.08; 574 participants; 4 trials; I2 = 68). Cancer-related mortality was lower in the
surgery group (20/115 (17.4%)) than in the radiofrequency ablation group (43/115 (37.4%)) (odds ratio 0.35, 95% CI 0.19 to 0.65;
230 participants; 1 trial). Serious adverse events (number of participants) was higher in the surgery group (14/60 (23.3%)) than in
the radiofrequency ablation group (1/60 (1.7%)) (odds ratio 17.96, 95% CI 2.28 to 141.60; 120 participants; 1 trial). The number
of serious adverse events was higher in the surgery group (adjusted rate 11.3 events per 100 participants) than in the radiofrequency
ablation group (3/186 (1.6 events per 100 participants)) (rate ratio 7.02, 95% CI 2.29 to 21.46; 391 participants; 2 trials; I2 = 0%).
None of the trials reported health-related quality of life. One trial was funded by a party with vested interests; three trials were funded
by parties without any vested.
Non-surgical interventions
The majority of participants had cirrhotic livers, and the hepatocellular carcinoma was of viral aetiology. Most trials did not report
the portal hypertension status of the participants, and none of the trials reported whether the participants received adjuvant antiviral
treatment or adjuvant immunotherapy. The average follow-up ranged from 6 months to 37 months (11 trials). Trial participants, who
were not eligible for surgery, were treated with radiofrequency ablation, laser ablation, microwave ablation, percutaneous acetic acid
injection, percutaneous alcohol injection, a combination of radiofrequency ablation with systemic chemotherapy, a combination of
radiofrequency ablation with percutaneous alcohol injection, a combination of transarterial chemoembolisation with percutaneous
alcohol injection, or a combination of transarterial chemoembolisation with radiofrequency ablation.
The mortality at maximal follow-up was higher in the percutaneous acetic acid injection (hazard ratio 1.77, 95% CI 1.12 to 2.79;
125 participants; 1 trial) and percutaneous alcohol injection (hazard ratio 1.49, 95% CI 1.18 to 1.88; 882 participants; 5 trials; I2 =
57%) groups compared with the radiofrequency ablation group. There was no evidence of a difference in all-cause mortality at maximal
follow-up for any of the other comparisons. The proportion of people with cancer-related mortality at maximal follow-up was higher
in the percutaneous alcohol injection group (adjusted proportion 16.8%) compared with the radiofrequency ablation group (20/232
(8.6%)) (odds ratio 2.18, 95% CI 1.22 to 3.89; 458 participants; 3 trials; I2 = 0%). There was no evidence of a difference in any of
the comparisons that reported serious adverse events (number of participants or number of events). None of the trials reported health-
related quality of life. Five trials were funded by parties without any vested interest; the source of funding was not available in the
remaining trials.
Authors’ conclusions
The evidence was of low or very low quality. There was no evidence of a difference in all-cause mortality at maximal follow-up
between surgery and radiofrequency ablation in people eligible for surgery. All-cause mortality at maximal follow-up was higher with
percutaneous acetic acid injection and percutaneous alcohol injection than with radiofrequency ablation in people not eligible for
surgery. There was no evidence of a difference in all-cause mortality at maximal follow-up for the other comparisons. High-quality
RCTs designed to assess clinically important differences in all-cause mortality and health-related quality of life, and having an adequate
follow-up period (approximately five years) are needed.
P L A I N L A N G U A G E S U M M A R Y
Treatment of very early- or early-stage primary liver cancer (hepatocellular carcinoma)
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Background
Hepatocellular carcinoma (primary liver cancer) arises from the liver cells and is distinct from cancer arising from other parts of the body
and spreading to the liver. The Barcelona Clinic Liver Cancer (BCLC) group staging classifies cancer based on patient’s life expectancy.
It is broadly based on the size of the cancer, number of cancers in the liver, how well the liver functions, and whether one’s activities
are affected by the cancer. People with very early- or early-stage hepatocellular carcinoma have single cancer or multiple small cancers
confined to the liver, have good liver function, and no restriction of activities. There is significant uncertainty in the management of
early-stage hepatocellular carcinoma. Therefore, we searched literature databases for randomised clinical trials (RCTs) on the topic until
September 2016. We excluded trials in which participants had previously undergone liver transplantation. Apart from using standard
Cochrane methods, which allow comparison of only two treatments at a time, we planned to use advanced methods described in full
in the review.
Study characteristics of included trials
Four trials (593 participants; 574 participants included for one or more analyses) compared surgery (removal of part of the liver
containing cancer) versus radiofrequency ablation (cancer destruction using heat generated by electric current) in people with early
hepatocellular carcinoma, eligible to undergo surgery; and 14 trials (2533 participants; 2494 participants included for various analyses)
compared different non-surgical interventions in people with early hepatocellular carcinoma, not eligible to undergo surgery.
Key results
Surgery versus radiofrequency ablation
The majority of participants had cirrhotic livers, and the hepatocellular carcinoma was of viral cause. The trials did not report the
participants’ portal hypertension status or whether they received adjuvant antiviral treatment or adjuvant immunotherapy. Three trials
reported average follow-up (range 29 months to 42 months). One trial was funded by a party with vested interests; three trials were
funded by parties without any vested..
In people eligible for surgery, there was no evidence of a difference in death between radiofrequency ablation and surgery; although
there were fewer deaths due to cancer in the surgery group. There were more serious complications in the the surgery group than in
the radiofrequency ablation group. None of the trials reported health-related quality of life.
Non-surgical interventions
The majority of participants had cirrhotic livers, and the hepatocellular carcinoma was of viral cause. Most trials did not report the
portal hypertension status of the participants, and none reported whether the participants received adjuvant antiviral treatment or
adjuvant immunotherapy. Eleven trials reported average follow-up (range 6 months to 37 months). Trial participants, who were not
eligible for surgery, were treated with radiofrequency ablation, laser ablation (cancer destruction using laser), microwave ablation
(cancer destruction using microwaves), percutaneous acetic acid injection (cancer destruction using vinegar), percutaneous alcohol
injection (cancer destruction using alcohol), a combination of radiofrequency ablation with systemic chemotherapy, a combination of
radiofrequency ablation with percutaneous alcohol injection, a combination of transarterial chemoembolisation (blocking the artery
supplying the cancer with beads containing chemotherapy drugs) with percutaneous alcohol injection, or a combination of transarterial
chemoembolisation with radiofrequency ablation. Five trials were funded by parties without any vested interest; the source of funding
was not available in the remaining trials.
In people not eligible for surgery, the percentage of people who died during the follow-up period was higher in the percutaneous acetic
acid injection and percutaneous alcohol injection groups than in the radiofrequency ablation group. There was no evidence of any
difference in the percentage of people who died between any of the remaining comparisons. The percentage of people who died because
of cancer was also higher in the percutaneous alcohol injection group than in the radiofrequency ablation group. There was no evidence
of any difference in the percentage of people who died because of cancer between any of the remaining comparisons. None of the trials
reported health-related quality of life at any time point.
Quality of evidence
The overall quality of evidence was low or very low because of the way trials were conducted. Therefore, the conclusions made could
overestimate the benefits or underestimate the harms of a given treatment. Further high-quality RCTs are needed.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Surgery versus radiof requency ablat ion for people with early- or very early-stage hepatocellular carcinoma
Patient or population: people with early- or very early-stage hepatocellular carcinoma eligible for surgery
Settings: secondary or tert iary care
Intervention: surgery
Control: radiof requency ablat ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Radiofrequency ablation Surgery
All- cause mortality at max-
imal follow-up
Follow-up: 29 months to 42
months
300 per 1000 248 per 1000
(193 to 320)
HR 0.80
(0.60 to 1.08)
574
(4 trials)
⊕©©©
very low1,2,3,4
Cancer- related mortality at
maximal follow-up
Follow-up: 42 months
374 per 1000 173 per 1000
(102 to 280)
OR 0.35
(0.19 to 0.65)
230
(1 trial)
⊕⊕©©
low1,2
Serious adverse events
(number of participants)
Follow-up: postprocedural
(very short term)
17 per 1000 233 per 1000
(37 to 706)
OR 17.96
(2.28 to 141.6)
120
(1 trial)
⊕⊕©©
low1,2
Serious adverse events
(number of events)
Follow-up: postprocedural
(very short term)
108 per 1000 758 per 1000
(247 to 2318)
Rate ratio 7.02
(2.29 to 21.46)
391
(2 trials)
⊕⊕©©
low1,2
Health- related quality of
life
None of the trials reported this outcome.
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* The basis for the assumed risk f or all-cause mortality is the approximate control group proport ions at two to three years reported in the Kaplan-Meier curves in the trials that
reported mortality at maximal-follow-up. We have assumed proport ional hazards. The basis for the assumed risk f or other outcomes is based on the mean control group
proport ion. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; HR: hazard rat io; OR: odds rat io; RR: rate rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded one level because of within-study risk of bias: there was unclear or high risk of bias in the trial(s).
2Downgraded one level because of imprecision: the sample size was small.
3Downgraded one level because of imprecision: the conf idence intervals overlapped clinically signif icant ef fect and clinically
insignif icant ef fect.
4Downgraded one level because of inconsistency: there was substant ial unexplained heterogeneity.
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B A C K G R O U N D
Description of the condition
Hepatocellular carcinoma is primary cancer of the liver cells and
is the major primary liver cancer (Bosetti 2014; NCBI 2014).
An estimated 782,000 people develop hepatocellular carcinoma,
and 746,000 people die because of primary liver cancer each
year worldwide (IARC 2014a). It is the sixth most common can-
cer overall, with an age-standardised incidence rate of 10.1 per
100,000 population per year (IARC 2014b). It is the second most
commoncause of death fromcancerworldwide (IARC 2014a). It is
more common inmen thanwomen (IARC 2014a). There is global
variation in the incidence of and mortality related to primary liver
cancer. Approximately half of all primary liver cancers occur in
China (395,000 people per year). Northern Europe has the lowest
incidence of primary liver cancer (IARC 2014a). The incidence of
hepatocellular carcinoma has increased in many countries (Davila
2004; Jepsen 2007; Pocobelli 2008; Taura 2009; von Hahn 2011;
Witjes 2012; Bosetti 2014; Ladep 2014), which is attributed to
hepatitis C virus infection (Davila 2004; Taura 2009). Alcohol-
related liver disease and hepatitis B and C virus are considered to
be major risk factors for hepatocellular carcinoma (Davila 2004;
Bosetti 2014). Other risk factors include aflatoxin in foods (toxins
produced by Aspergillus fungus), smoking, being overweight, and
diabetes (Lee 2009; Polesel 2009; Chen 2012; Liu 2012; Bosetti
2014; Turati 2014). The incidence of hepatocellular carcinoma
is higher in people with a family history of hepatocellular carci-
noma, and lower in people with high intake of vegetables and cof-
fee (Turati 2012; Sang 2013; Bosetti 2014; Yang 2014). The asso-
ciation between oral contraceptives and hepatocellular carcinoma
is unclear, and there is currently no evidence of an increased risk
in women using oral contraceptives when compared with women
who do not use oral contraceptives, based on one meta-analysis
of observational studies (Maheshwari 2007). Hepatocellular carci-
noma usually develops in cirrhotic livers, although it may also de-
velop in non-cirrhotic livers (Arnaoutakis 2014; Gaddikeri 2014).
Hepatocellular carcinomas that develop in non-cirrhotic livers are
usually solitary but larger compared to hepatocellular carcinomas
that develop in cirrhotic livers (Gaddikeri 2014). The role of rou-
tine screening for hepatocellular carcinoma in people with chronic
liver disease is controversial, with one systematic review conclud-
ing that there is no evidence of benefit of routine screening for
people with hepatocellular carcinoma (Aghoram 2012; Kansagara
2014).
Description of the intervention
Several classifications of hepatocellular carcinoma have been pro-
posed, including clinical staging classifications, histopathological
classifications, andmolecular classifications (Wu 1996;Henderson
2003; Van Deusen 2005; Cillo 2006; Nanashima 2006; van
Malenstein 2011a). Of these, the Barcelona Clinic Liver Cancer
(BCLC) staging system, Llovet 1999 and Llovet 2003, and the
Milan criteria, Mazzaferro 1996, are commonly used and are im-
portant classification systems for determining the management of
hepatocellular carcinoma. Appendix 1 and Appendix 2 show these
classification systems in detail. Stage 0 (very early hepatocellular
carcinoma) and stage A (early hepatocellular carcinoma) of BCLC
staging correspond approximately to tumours falling within the
Milan criteria 1, although stage A of the BCLC staging system in-
cludes single tumour of any size, while to fall within Milan criteria
1 a single tumour should be less than 5 cm. This review examined
the treatment options for people with very early hepatocellular
carcinoma (single nodule less than 2 cm in diameter, Child-Pugh
A cirrhosis, and performance status 0 (fully functional)) and early
hepatocellular carcinoma (single tumour or two or three lesions
less than 3 cm in diameter with no evidence of vascular invasion or
extrahepatic spread, Child-PughA or B cirrhosis, and performance
status 0) (stages 0 and A of the BCLC staging system). A separate
review covers the treatment options for people with intermediate
hepatocellular carcinoma (largemultinodular tumours with no ev-
idence of vascular invasion or extrahepatic spread; stage B BCLC
staging system, Child-Pugh A or B cirrhosis, and performance sta-
tus 0) (Roccarina 2017). There are currently no Cochrane system-
atic reviews that cover all of the treatments for advanced hepato-
cellular carcinoma (vascular invasion or extrahepatic spread; stage
C BCLC staging system) or end-stage hepatocellular carcinoma
(poor performance status or Child-Pugh C liver functional status;
stage D BCLC staging system).
Various treatments are aimed at curing hepatocellular carcinoma.
These can be broadly classified as surgical (liver resection and liver
transplantation), ablative techniques, and transarterial embolisa-
tion (TAE) or transarterial chemoembolisation (TACE).
The surgical management of hepatocellular carcinoma is in the
formof liver resection and liver transplantation (Bruix 2011; EASL
2012; Asham 2013). Liver resection is performed to ensure that
all of the tumours are removed with adequate remnant liver to
carry out the normal functions of the liver (Asham 2013). Liver re-
section is usually performed by open technique, although laparo-
scopic (keyhole) liver resectionmay be performed in select patients
(Nguyen 2009). Complications related to liver resection include
mortality, liver failure, bile leak, bleeding, liver abscess, abdominal
abscess, wound infection, and general complications such as heart
failure and renal failure (Nguyen 2009; Xiong 2012). Liver trans-
plantation involves removal of the diseased liver and transplanting
a liver graft from a donor (usually a cadaveric donor) (SRTR 2012;
NHSBT 2014). Living-donor liver transplantation is associated
with increased complications and re-transplantation and consti-
tutes only a small proportion of the global liver transplantations
(Wan 2014). Complications of liver transplantation include mor-
tality, graft failure, graft rejection, biliary stricture, hepatic artery
thrombosis, and wound infections (Gurusamy 2014; Wan 2014).
6Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ablation is usually in the form of radiofrequency ablation (Bruix
2011; EASL 2012; Asham 2013), however other modalities exist
such as chemical ablation using percutaneous alcohol injections,
percutaneous acetic acid injections, and thermal ablations such as
microwave ablation, laser (light amplification by stimulated emis-
sion of radiation) ablation, cryoablation (tissue ablation by freez-
ing), high-intensity focused ultrasound, and irreversible electropo-
ration (NanoKnife) (Head 2004; Germani 2010; Sindram 2010;
Chan 2013a). Complications related to radiofrequency ablation
include mortality, liver failure, bleeding, liver abscess, bile duct in-
juries, and tumour dissemination through the needle tract (’seed-
ing’) or into the peritoneum (Chan 2013a; McDermott 2013).
Transarterial embolisation involves embolisation of the hepatic
artery without using any chemotherapeutic agents, while TACE
involves injection of a chemotherapeutic agent prior to embolisa-
tion of the hepatic artery (Pleguezuelo 2008; Oliveri 2011). Ma-
jor complications of TAE and TACE include mortality, liver fail-
ure, liver and splenic abscesses, acute cholecystitis, damage to the
bile ducts, renal failure, and severe upper gastrointestinal bleeding
(Pleguezuelo 2008; Oliveri 2011).
How the intervention might work
Liver resection and liver transplantation work by removing the
cancer. Chemical ablations using alcohol injections and acetic acid
injections work by destruction of cancer tissue by the chemicals
used (Sindram 2010). Thermal ablations cause destruction of can-
cer tissue by heat or cold (Sindram 2010). Transarterial embolisa-
tion and TACE cause ischaemia to the tumour, thereby inducing
tumour necrosis (Pleguezuelo 2008; Oliveri 2011). Transarterial
chemoembolisation combines the effect of chemotherapy agents,
which inhibit the tumour, with the effect of ischaemia on the
tumour, although the main effect of TACE may be due to the
ischaemia rather than the chemotherapy delivered via the artery
(Pleguezuelo 2008).
Why it is important to do this review
Current guidelines on the management of hepatocellular carci-
noma by the European Association for the Study of the Liver
(EASL) and the American Association for the Study of Liver Dis-
eases (AASLD) recommend the following for peoplewith early and
very early hepatocellular carcinoma (Bruix 2011; EASL 2012).
• Liver resection for single tumour provided that the portal
pressure and bilirubin levels are normal.
• Liver transplantation for two or three nodules less than 3
cm or a single nodule in the presence of increased portal pressure
or abnormal bilirubin levels provided that there are no associated
diseases that preclude liver transplantation.
• Radiofrequency ablation for two or three nodules less than
3 cm or a single nodule in the presence of increased portal
pressure or abnormal bilirubin levels in the presence of associated
diseases that preclude liver transplantation.
However, it should be noted that people with hepatocellular car-
cinoma must compete with other people waiting for liver trans-
plantation. In 2012, pre-transplant deaths occurred at the rate of
5.8 deaths per 100 waitlist years in the USA (SRTR 2012), and
in the financial year to the end of March 2014, 12% of people
on the liver transplant waiting list in the UK died or became too
unwell to be transplanted (NHSBT 2014). This indicates an or-
gan shortage necessitating an organ allocation policy. The Milan
criteria are now used for organ allocation in many countries. In
the USA, eligible people with hepatocellular carcinoma are given
exceptional status to limit their presence on the waiting list, as
waiting increases the chance of tumour progression or dissemi-
nation (OPTN 2014). To be considered eligible for liver trans-
plantation, people with hepatocellular carcinoma must fulfil the
Milan criteria as well as having a minimum tumour size of 2 cm
if they have a single tumour and a minimum tumour size of 1 cm
each if they have two or three lesions (OPTN 2014). There thus
appears to be a discrepancy in the recommendations by AASLD
and EASL regarding organ allocation policy concerning people
with early or very early hepatocellular carcinoma. Network meta-
analysis allows the combination of the direct and indirect evidence
and permits ranking of different interventions in terms of the dif-
ferent outcomes (Salanti 2011; Salanti 2012). No network meta-
analysis on the different interventions for early or very early hepa-
tocellular carcinoma has been performed. This systematic review
and attempted network meta-analysis intended to provide the best
level of evidence for the role of different treatment options used
for people with early or very early hepatocellular carcinoma.
O B J E C T I V E S
To assess the comparative benefits and harms of different inter-
ventions used in the treatment of early or very early hepatocellular
carcinoma through a network meta-analysis and to generate rank-
ings of the available interventions according to their safety and
efficacy. However, it was not possible to assess whether the po-
tential effect modifiers were similar across different comparisons.
Therefore, we did not perform the network meta-analysis and in-
stead assessed the benefits and harms of different interventions
versus each other or versus sham or no intervention using standard
Cochrane methodology.
When more trials become available with adequate description of
potential effect modifiers, we will attempt to conduct network
meta-analysis in order to generate rankings of the available inter-
ventions according to their safety and efficacy. Therefore, we have
retained the planned methodology for network meta-analysis in
Appendix 3.Once data appear allowing for the conduct of network
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meta-analysis, Appendix 3 will be moved back into the Methods
section.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered only randomised clinical trials irrespective of lan-
guage, publication status, or date of publication. We excluded
studies of other design because of the risk of bias in such studies,
while being aware that such exclusions make us focus much more
on potential benefits and not fully assess the risks of serious adverse
events as well as the risks of adverse events.
Types of participants
We included randomised clinical trials with participants with early
or very early hepatocellular carcinoma irrespective of the presence
of cirrhosis, size of tumour(s), and number of tumours (provided
that they met the criteria of early or very early hepatocellular car-
cinoma (i.e. BCLC stages 0 and A)), presence or absence of portal
hypertension, aetiology of hepatocellular carcinoma, and the fu-
ture remnant liver volume. We excluded randomised clinical trials
in which participants were previously liver transplanted.
Types of interventions
We planned to include any of the following interventions that
are possible treatments for early or very early hepatocellular carci-
noma, either alone or in combination tested versus each other or
versus sham or no intervention.
Some of the interventions that we considered were:
• liver resection;
• liver transplantation;
• radiofrequency ablation;
• microwave ablation;
• other ablations (laser ablation, cryoablation, high-intensity
focused ultrasound, irreversible electroporation);
• alcohol injection;
• acetic acid injection;
• TAE;
• TACE.
The above list is not exhaustive. If we identified interventions of
which were unaware, we considered them as eligible and included
them in the review if they are used primarily for the treatment
of hepatocellular carcinoma. If liver resection or liver transplan-
tation is combined with ablation, TAE, or TACE, we planned to
categorise the intervention as liver resection or liver transplanta-
tion, because liver resection and liver transplantation are themajor
components in such interventions, with ablation, TAE, or TACE
playing an exclusively supportive role to liver resection or liver
transplantation. However, we planned to exclude such interven-
tions from a sensitivity analysis (see Sensitivity analysis). If we
found a sufficient number of trials (at least one in each category)
on one or more of the other methods of ablation (laser ablation,
cryoablation, high-intensity focused ultrasound, irreversible elec-
troporation), we considered the specific method of ablation with
sufficient trials as a separate intervention (node).
Types of outcome measures
We assessed the comparative benefits and harms of available inter-
ventions aimed at treating people with early or very early hepato-
cellular carcinoma for the following outcomes.
Primary outcomes
1. Mortality at maximal follow-up (time to death):
i) all-cause mortality;
ii) cancer-related mortality.
2. Mortality:
i) short-term mortality (up to one year);
ii) medium-term mortality (one to five years).
3. Adverse events (within three months of cessation of
treatment). Depending on the availability of data, we planned to
attempt to classify adverse events as serious and non-serious. We
defined a serious adverse event as any event that would increase
mortality; was life-threatening; required hospitalisation; resulted
in persistent or significant disability; was a congenital anomaly/
birth defect; or any important medical event that might
jeopardise the person or require intervention to prevent it. We
defined a non-serious adverse event as any untoward medical
occurrence not necessarily having a causal relationship with the
treatment but resulting in a dose reduction or discontinuation of
treatment (any time after commencement of treatment)
(ICH-GCP 1997). We used the definition employed by study
authors for non-serious and serious adverse events:
i) proportion of participants with serious adverse events;
ii) number of serious adverse events;
iii) proportion of participants with any type of adverse
event;
iv) number of any type of adverse event.
4. Quality of life as defined in the included trials using a
validated scale such as EQ-5D or 36-Item Short Form Health
Survey (SF-36) (EuroQol 2014; Ware 2014):
i) short term (up to one year);
ii) medium term (one to five years);
iii) long term (beyond five years).
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We considered long-term quality of life more important than
short- or medium-term quality of life, although short- or medium-
term quality of life were also important primary outcomes.
Secondary outcomes
1. Disease recurrence (maximum follow-up):
i) proportion of participants with hepatocellular
carcinoma recurrence (includes recurrence in the liver and
metastatic disease);
ii) proportion of participants with local recurrence
(recurrence in the liver).
2. Length of hospital stay for the treatment and treatment-
related complications. If treatment was performed in two or
more sessions, we planned to calculate the total length of
hospital stay for all the sessions. Similarly, we planned to include
length of hospital stay for readmissions within 30 days of
treatment because of treatment-related complications in the
length of hospital stay.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) in the Cochrane Library, MEDLINE (OvidSP),
Embase (OvidSP), and Science Citation Index Expanded (Web of
Knowledge) from inception to 30 September 2016 for randomised
clinical trials comparing two or more of the above interventions
(Royle 2003). We searched for all possible comparisons formed
by the interventions of interest. To identify further ongoing or
completed trials, we also searched the World Health Organiza-
tion International Clinical Trials Registry Platform search portal
(apps.who.int/trialsearch/), which searches various trial registers,
including ISRCTN (www.isrctn.com/) and ClinicalTrials.gov (
clinicaltrials.gov/). Appendix 4 shows the search strategies used
and the time spans of the searches.
Searching other resources
We searched the references of the identified trials and the existing
Cochrane reviews on hepatocellular carcinoma to identify addi-
tional trials for inclusion.
Data collection and analysis
Selection of studies
Two review authors (KG, AM, or DR between them) indepen-
dently identified the trials for inclusion by screening the titles and
abstracts. We sought full-text articles for any references that at least
one of the review authors identified for potential inclusion. We
selected trials for inclusion based on the full-text articles. A list of
the excluded full-text references with reasons for their exclusion
can be found in the Characteristics of excluded studies table. We
have also listed any ongoing trials identified primarily through the
search of the clinical trial registers for further follow-up. Any dis-
crepancies were resolved through discussion.
Data extraction and management
Two review authors (KG and AMor DR) independently extracted
the following data.
• Outcome data (for each outcome and for each treatment
arm whenever applicable):
◦ number of participants randomised;
◦ number of participants included for the analysis;
◦ number of participants with events for binary
outcomes, mean and standard deviation for continuous
outcomes, number of events for count outcomes, and the
number of participants with events and the mean follow-up
period for time-to-event outcomes;
◦ definition of outcomes or scale used if appropriate.
• Data on potential effect modifiers:
◦ participant characteristics such as age, sex,
comorbidities, proportion of people with or without cirrhosis,
tumour size, number of tumours, presence of portal
hypertension, aetiology of hepatocellular carcinoma, and
adjuvant treatments such as immunotherapy;
◦ details of the intervention and control (including dose,
frequency, and duration);
◦ risk of bias (assessment of risk of bias in included
studies).
• Other data:
◦ year and language of publication;
◦ country in which the participants were recruited;
◦ year(s) in which the trial was conducted;
◦ inclusion and exclusion criteria;
◦ follow-up time points of the outcome.
If available, we planned to obtain separate data for people with and
without cirrhosis; single tumour less than 5 cm compared to single
tumour 5 cm or greater compared to multiple tumours; presence
compared to absence of portal hypertension; and viral versus non-
viral aetiology. We contacted the authors for unclear or missing
information. If there was any doubt as to whether trials shared the
same participants, completely or partially (by identifying common
authors and centres), we planned to contact the trial authors to
clarify whether the trial report was duplicated. Any differences in
opinion were resolved through discussion.
Assessment of risk of bias in included studies
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We followed the guidance given in the Cochrane Handbook for
Systematic Reviews of Interventions and described in the Cochrane
Hepato-Biliary GroupModule to assess the risk of bias in included
trials (Higgins 2011; Gluud 2016). Specifically, we assessed the
risk of bias in included trials for the following domains using
the methods below (Schulz 1995; Moher 1998; Kjaergard 2001;
Wood 2008; Savovi 2012a; Savovi 2012b; Lundh 2017).
Allocation sequence generation
• Low risk of bias: sequence generation was achieved using
computer random number generation or a random number
table. Drawing lots, tossing a coin, shuffling cards, and throwing
dice were adequate if performed by an independent person not
otherwise involved in the trial.
• Uncertain risk of bias: the method of sequence generation
was not specified.
• High risk of bias: the sequence generation method was not
random.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. Allocation
was controlled by a central and independent randomisation unit.
The allocation sequence was unknown to the investigators (e.g. if
the allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Uncertain risk of bias: the method used to conceal the
allocation was not described so that intervention allocations may
have been foreseen in advance of, or during, enrolment.
• High risk of bias: the allocation sequence was likely to be
known to the investigators who assigned the participants.
Blinding of participants and personnel
• Low risk of bias: blinding was performed adequately, or the
care that participants received was not likely to be influenced by
lack of blinding.
• Uncertain risk of bias: there was insufficient information to
assess whether blinding was likely to induce bias on the results.
• High risk of bias: no blinding or incomplete blinding, and
the care that participants received was likely to be influenced by
lack of blinding.
Blinding of outcome assessors
• Low risk of bias: blinding was performed adequately, or the
assessment of outcomes was not likely to be influenced by lack of
blinding.
• Uncertain risk of bias: there was insufficient information to
assess whether blinding was likely to induce bias on the results.
• High risk of bias: no blinding or incomplete blinding, and
the assessment of outcomes was likely to be influenced by lack of
blinding.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. Sufficient
methods, such as multiple imputation, were employed to handle
missing data.
• Uncertain risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to induce bias on the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported the following predefined
outcomes: at least medium-term or long-term mortality and
treatment-related adverse events. If the original trial protocol was
available, the outcomes should be those called for in that
protocol. If the trial protocol was obtained from a trial registry
(e.g. ClinicalTrials.gov), the outcomes sought should be those
enumerated in the original protocol if the trial protocol was
registered before or at the time that the trial was begun. If the
trial protocol was registered after the trial was begun, those
outcomes were not be considered to be reliable.
• Unclear risk of bias: not all predefined or clinically relevant
and reasonably expected outcomes were reported fully, or it was
unclear whether data on these outcomes were recorded or not.
• High risk of bias: one or more predefined or clinically
relevant and reasonably expected outcomes were not reported,
despite the fact that data on these outcomes should have been
likely to have been available and even recorded.
For-profit bias
• Low risk of bias: the trial appeared to be free of industry
sponsorship or other type of for-profit support that could
manipulate the trial design, conductance, or results of the trial.
• Uncertain risk of bias: the trial may or may not be free of
for-profit bias, as no information on clinical trial support or
sponsorship was provided.
• High risk of bias: the trial was sponsored by industry or
received other type of for-profit support.
Other bias
• Low risk of bias: the trial appeared to be free of other
components (e.g. inappropriate control or dose or
administration of control) that could put it at risk of bias.
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• Uncertain risk of bias: the trial may or may not be free of
other components that could put it at risk of bias.
• High risk of bias: there were other factors in the trial that
could put it at risk of bias (e.g. inappropriate control or dose or
administration of control).
We considered a trial to be at low risk of bias if the trial was assessed
as at low risk of bias across all domains. Otherwise, we considered
trials at uncertain risk of bias or at high risk of bias regarding one
or more domains as at high risk of bias. As blinding of healthcare
providers is impossible for all of the comparisons, and blinding
of participants is unlikely for comparisons involving surgery, we
planned to assess the potential influence of lack on blinding on
the outcomes carefully. Because of the potential influence of lack
of blinding, we planned to classify the trials as at high risk of bias
for all outcomes other than mortality.
Measures of treatment effect
For dichotomous variables (e.g. short-term mortality, medium-
term mortality, and proportion of participants with adverse
events), we calculated the odds ratio with 95% confidence interval
(CI). For continuous variables (e.g. hospital stay and quality of
life reported on the same scale), we planned to calculate the mean
difference with 95% CI. We planned to use standardised mean
difference values with 95% CI for quality of life if included trials
use different scales. For count outcomes (e.g. number of adverse
events), we calculated the rate ratio with 95% CI. For time-to-
event data (e.g. mortality at maximal follow-up), we used hazard
ratio with 95% CI.
Unit of analysis issues
Cluster randomised clinical trials
As expected, we found no cluster randomised clinical trials. How-
ever, had we found them, we planned to include them provided
that the effect estimate adjusted for cluster correlation was avail-
able.
Cross-over randomised clinical trials
As expected, we found no cross-over randomised clinical trials.
Had we identified any, we planned to only include the outcomes
after the period of first intervention because the first intervention
may have a permanent impact on the outcome (i.e. have a residual
effect).
Trials with multiple treatment groups
We collected data for all trial intervention groups that met the
inclusion criteria.
Dealing with missing data
We performed an intention-to-treat analysis whenever possible
(Newell 1992). Otherwise, we used the data that were available
to us (e.g. a trial may have reported only per-protocol analysis
results). As ’per-protocol’ analyses may be biased, we planned to
conduct best-worst case scenario analyses (good outcome in inter-
vention group and bad outcome in control group) and worst-best
case scenario analyses (bad outcome in intervention group and
good outcome in control group) as sensitivity analyses whenever
possible.
For continuous outcomes, we planned to impute the standard
deviation from P values according to guidance in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
If the data were likely to be normally distributed, we planned to
use themedian for meta-analysis when themean was not available.
If it was not possible to calculate the standard deviation from the
P value or the confidence intervals, we planned to impute the
standard deviation using the largest standard deviation in other
trials for that outcome. This form of imputation may decrease the
weight of the study for calculation of mean differences and may
bias the effect estimate to no effect for calculation of standardised
mean differences (Higgins 2011).
Assessment of heterogeneity
Weplanned to assess clinical and methodological heterogeneity by
carefully examining the characteristics and design of the included
trials. We planned to assess the presence of clinical heterogeneity
by comparing effect estimates in people with and without cirrho-
sis, presence of portal hypertension, aetiology of hepatocellular
carcinoma, and adjuvant treatment with immunotherapy. Differ-
ent study designs and risk of bias may contribute to methodolog-
ical heterogeneity.
We used the I2 test and Chi2 test for heterogeneity, and over-
lapping of CIs to assess heterogeneity. If we identified substantial
heterogeneity (clinical, methodological, or statistical), we planned
to explore and address heterogeneity in a subgroup analysis (see
Subgroup analysis and investigation of heterogeneity section).
Assessment of reporting biases
We planned to use visual asymmetry on a funnel plot to explore
reporting bias when at least 10 trials could be included for a di-
rect comparison (Egger 1997; Macaskill 2001). In the presence
of heterogeneity that could be explained by subgroup analysis, we
planned to produce a funnel plot for each subgroup when there
was an adequate number of trials. We planned to use the linear
regression approach described by Egger 1997 to determine funnel
plot asymmetry.
We also considered selective reporting as evidence of reporting
bias.
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Data synthesis
We performed the meta-analyses according to the recommenda-
tions of Cochrane (Higgins 2011), using the software package Re-
viewManager 5 (RevMan 2014).We used a random-effects model
and a fixed-effect model (DerSimonian 1986; DeMets 1987). In
the case of a discrepancy between the two models, we reported
both results; otherwise, we reported only the results from the fixed-
effect model.
Calculation of required information size and Trial Sequential
Analysis
For calculation of the required information size, see Appendix 5.
We performed Trial Sequential Analysis to control the risk of ran-
dom errors when at least two trials were included for all-cause
mortality at maximal follow-up and health-related quality of life,
the two outcomes that determine whether the treatment should be
given (Wetterslev 2008; Thorlund 2011; TSA 2011). We used an
alpha error as per guidance of Jakobsen 2014, power of 90% (beta
error of 10%), a relative risk reduction of 20%, a control group
proportion observed in the trials, and the heterogeneity observed
in the meta-analysis. As the only outcome was mortality at max-
imal follow-up, which is a time-to-event outcome, we performed
the Trial Sequential Analysis using Stata/SE 14.2 employingmeth-
ods suggested by Miladinovic 2013.
Subgroup analysis and investigation of heterogeneity
Weplanned to assess the differences in the effect estimates between
the following subgroups.
• Trials at low risk of bias compared to trials at high risk of
bias.
• People with and without cirrhosis.
• Very early compared to early hepatocellular carcinoma.
• Presence compared to absence of portal hypertension.
• Viral aetiology compared to non-viral aetiology.
• Use of immunotherapy or antiviral therapy as adjuvant
therapy compared to no use.
Weplanned touse theChi2 test for subgroupdifferences to identify
subgroup differences.
Sensitivity analysis
If a trial reported only per-protocol analysis results, we planned to
re-analyse the results using the best-worst case scenario and worst-
best case scenario analyses as sensitivity analyseswhenever possible.
In addition, we planned to exclude trials in which liver resection or
liver transplantation was combined with ablation, TAE, or TACE.
Presentation of results and GRADE assessments
We have reported all-cause mortality, cancer-related mortality, se-
rious adverse events, and health-related quality of life, the out-
comes that determine the management of people with early- or
very early-stage hepatocellular carcinoma, in a ’Summary of find-
ings’ table format, downgrading the quality of evidence for risk
of bias, inconsistency, indirectness, imprecision, and publication
bias using GRADE (Guyatt 2011). We have presented only com-
parisons in which at least two trials were included for one or more
of these outcomes.
R E S U L T S
Description of studies
Results of the search
We identified 7717 references through electronic searches ofCEN-
TRAL (N= 615), MEDLINE (N = 3753), Embase (N = 809), Sci-
ence Citation Index Expanded (N = 2277), World Health Orga-
nization International Clinical Trials Registry Platform (N = 85),
and ClinicalTrials.gov (N = 178). After removing 1684 duplicates,
we obtained 6033 references.We then excluded 5969 clearly irrel-
evant references through screening titles and reading abstracts. We
retrieved 64 references for further assessment. We identified no
references through scanning reference lists of the identified ran-
domised trials. We excluded 44 references for the reasons listed in
the Characteristics of excluded studies table. A total of 20 refer-
ences (18 trials) met the inclusion criteria. The reference flow is
summarised in the study flow diagram (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Eighteen trials met the inclusion criteria for this review: four trials
(593 participants; 574 participants included for one or more anal-
yses) compared surgery versus radiofrequency ablation in people
with early hepatocellular carcinoma who were eligible to undergo
surgery, while 14 trials (2533 participants; 2494 participants in-
cluded for various analyses) compared different non-surgical inter-
ventions in people with early hepatocellular carcinoma who were
not eligible to undergo surgery (this was clear from the inclusion
criteria in the trials). We have listed the comparisons included in
the trials and the follow-up period in the trials in Table 1.
Participants eligible for surgery
All four included trials compared surgery with radiofrequency
ablation (Chen 2006; Huang 2010; Fang 2014; Lee 2014). It
should be noted that none of the trials included liver transplan-
tation or sham treatment or no treatment as one of the compar-
ison groups. The average age in the trials that reported this in-
formation ranged from 51 years to 56 years. The proportion of
females in the trials that reported this information ranged from
18.6% to 28.7%.Three trials included participants with andwith-
out cirrhosis (Chen 2006; Huang 2010; Fang 2014). The fourth
trial did not report the cirrhosis status of participants (Lee 2014).
The proportion of participants who had cirrhosis was 61.7% and
84.2% in the two trials that reported this information (Huang
2010; Fang 2014). One trial included participants with early hep-
atocellular carcinoma but did not include participants with very
early hepatocellular carcinoma (Lee 2014). The remaining trials
did not report the proportion of participants with very early hep-
atocellular carcinoma. The proportion of participants with viral
aetiology was 89.2% and 93.5% in the two trials that reported this
information (Huang 2010; Fang 2014). The remaining two trials
did not report this information (Chen 2006; Lee 2014). None
of the trials reported the proportion of participants who received
adjuvant antiviral therapy or adjuvant immunotherapy. The mean
or median follow-up in the trials ranged from 29 months to 42
months in the three trials that provided this information (Chen
2006; Huang 2010; Fang 2014).
Source of funding
Three trials did not receive any additional funding or were funded
by parties without any vested interest in the results (Chen 2006;
Huang 2010; Fang 2014). One trial was funded by a party with
vested interest in the results (Lee 2014).
Participants not eligible for surgery
Fourteen trials included only participants who were not eligible
for surgery and compared various non-surgical interventions: ra-
diofrequency ablation, laser ablation, microwave ablation, per-
cutaneous acetic acid injection, percutaneous alcohol injection,
a combination of radiofrequency ablation with systemic chemo-
therapy, a combination of radiofrequency ablation with percuta-
neous alcohol injection, a combination of transarterial chemoem-
bolisation with percutaneous alcohol injection, or a combination
of transarterial chemoembolisation with radiofrequency ablation.
None of the trials included sham treatment or no treatment as
one of the comparison groups. The average age in the trials that
reported this information ranged from 49 years to 72 years. The
proportion of females in the trials that reported this information
ranged from 11.1% to 42.3%. Eight trials only included partici-
pants who had cirrhosis (Bolondi 1996; Shibata 2002; Lencioni
2003; Lin 2005; Brunello 2008; Giorgio 2011; Orlacchio 2014;
Costanzo 2015). The proportion of participants with cirrhosis was
85.3%and88.5% in the two trials that includedboth cirrhotic and
non-cirrhotic participants and reported the proportion of partici-
pants with cirrhosis (Koda 2001; Shiina 2005; Huang 2010; Fang
2014). The remaining four trials did not report this information
(Gan 2004; Chen 2005; Aikata 2006; El Kady 2013). One trial
included participants with early hepatocellular carcinoma, but did
not include participants with very early hepatocellular carcinoma
(El Kady 2013). The proportion of participants with very early
hepatocellular carcinoma in the only trial that reported this in-
formation was 25% (Giorgio 2011). The remaining trials did not
report the proportion of participants with very early hepatocellu-
lar carcinoma. Only one trial reported the proportion of partic-
ipants with portal hypertension (all 30 participants in this trial
had portal hypertension) (Orlacchio 2014). One trial included
hepatocellular carcinoma of viral aetiology only (Giorgio 2011).
The proportion of participants with viral aetiology ranged from
80.4% to 98.6% in the remaining seven trials that reported this
information (Koda 2001; Shibata 2002; Lencioni 2003; Lin 2005;
Shiina 2005; Brunello 2008; Orlacchio 2014). None of the trials
reported the proportion of participants who received adjuvant an-
tiviral therapy or adjuvant immunotherapy. The mean or median
follow-up in the trials ranged from 6 months to 37 months in
the 11 trials that provided this information (Bolondi 1996; Koda
2001; Shibata 2002; Lencioni 2003; Gan 2004; Lin 2005; Shiina
2005; Brunello 2008; Giorgio 2011; El Kady 2013; Orlacchio
2014).
Source of funding
Five trials did not receive any special funding or received funding
from parties without vested interest in the results (Brunello 2008;
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Giorgio 2011; El Kady 2013; Orlacchio 2014; Costanzo 2015).
The source of funding was not reported in the remaining trials.
Excluded studies
None of the trials met the inclusion criteria.
Risk of bias in included studies
The risk of bias is summarised in Figure 2, Figure 3, and Table 2.
None of the trials was at low risk of bias for all domains; hence,
we considered all trials to be at high risk of bias.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Surgery versus radiofrequency ablation
Two trials were at low risk of bias for random sequence generation
(Chen 2006; Huang 2010). The remaining trials were at unclear
risk of bias for random sequence generation. One trial was at low
risk of bias for allocation concealment (Huang 2010). The remain-
ing trials were at unclear risk of bias for allocation concealment.
We considered one trial that was at low risk of bias for random
sequence generation and allocation concealment to be at low risk
of allocation bias (Huang 2010).
Non-surgical interventions
Eight trials were at low risk of bias for random sequence generation
(Lencioni 2003; Lin 2005; Shiina 2005; Brunello 2008; Giorgio
2011; El Kady 2013; Orlacchio 2014; Costanzo 2015); none of
the trials was at high risk of bias for random sequence generation;
and six trials were at unclear risk of bias for random sequence
generation (Bolondi 1996; Koda 2001; Shibata 2002; Gan 2004;
Chen 2005; Aikata 2006).
Two trials were at low risk of bias for allocation concealment
(Brunello 2008; Giorgio 2011); none of the trials was at high
risk of bias for allocation concealment; and 12 trials were at un-
clear risk of bias for allocation concealment (Bolondi 1996; Koda
2001; Shibata 2002; Lencioni 2003; Gan 2004; Chen 2005; Lin
2005; Shiina 2005; Aikata 2006; El Kady 2013; Orlacchio 2014;
Costanzo 2015).
Overall, two trials were at low risk of selection bias (Brunello 2008;
Giorgio 2011); no trials were at high risk of selection bias; and 12
trials were at unclear risk of selection bias (Bolondi 1996; Koda
2001; Shibata 2002; Lencioni 2003; Gan 2004; Chen 2005; Lin
2005; Shiina 2005; Aikata 2006; El Kady 2013; Orlacchio 2014;
Costanzo 2015).
Blinding
Surgery versus radiofrequency ablation
One trial was at high risk of bias for blinding of participants and
healthcare providers (Huang 2010). The remaining trials were at
unclear risk of bias for blinding of participants and healthcare
providers.One trial was at high risk of bias for blinding of outcome
assessors (Huang 2010). The remaining trials were at unclear risk
of bias for blinding of outcome assessors. Overall, one trial was at
high risk of performance bias and detection bias. The remaining
trials were at unclear risk of performance bias and detection bias.
Non-surgical interventions
Five trials were at high risk of bias for blinding of participants
and health professionals (Shiina 2005; Brunello 2008; Giorgio
2011; Orlacchio 2014; Costanzo 2015); the remaining nine trials
were at unclear risk of bias for blinding of participants and health
professionals (Bolondi 1996; Koda 2001; Shibata 2002; Lencioni
2003; Gan 2004; Chen 2005; Lin 2005; Aikata 2006; El Kady
2013).
The trials had the same risk of bias for blinding of outcome asses-
sors domain as for the blinding of participants and health profes-
sionals domain.
Incomplete outcome data
Surgery versus radiofrequency ablation
One trial was at low risk of bias for incomplete outcome data
(attrition bias) (Huang 2010). One trial was at high risk of bias
for incomplete outcome data (attrition bias) (Chen 2006). The
remaining trialswere at unclear risk of bias for incomplete outcome
data (attrition bias).
Non-surgical interventions
Eight trials were at low risk of bias for incomplete outcome data
(attrition bias) (Shibata 2002; Lin 2005; Shiina 2005; Brunello
2008; Giorgio 2011; El Kady 2013; Orlacchio 2014; Costanzo
2015); two trials were at high risk of bias for incomplete outcome
data (attrition bias) (Lencioni 2003; Gan 2004); and four trials
were at unclear risk of bias for incomplete outcome data (attrition
bias) (Bolondi 1996; Koda 2001; Chen 2005; Aikata 2006).
Selective reporting
Surgery versus radiofrequency ablation
All four trials were at low risk of bias for selective reporting (re-
porting bias) (Chen 2006; Huang 2010; Fang 2014; Lee 2014).
Non-surgical interventions
Eleven trials were at low risk of bias for selective reporting (re-
porting bias) (Koda 2001; Lencioni 2003; Chen 2005; Lin 2005;
Shiina 2005; Aikata 2006; Brunello 2008; Giorgio 2011; El Kady
2013; Orlacchio 2014; Costanzo 2015); three trials were at high
risk of bias for selective reporting (reporting bias) (Bolondi 1996;
Shibata 2002; Gan 2004); and none of the trials was at unclear
risk of bias for selective reporting (reporting bias).
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Other potential sources of bias
Surgery versus radiofrequency ablation
For-profit bias: Three trials did not receive any additional funding
or were funded by parties without any vested interest in the results
(Chen 2006; Huang 2010; Fang 2014). One trial was funded by
parties with vested interest in the results (Lee 2014).
We noted no other bias in any of the trials.
Non-surgical interventions
For-profit bias: Five trials were at low risk of for-profit bias
(Brunello 2008; Giorgio 2011; El Kady 2013; Orlacchio 2014;
Costanzo 2015); none of the trials was at high risk of for-profit
bias; nine trials were at unclear risk of for-profit bias (Bolondi
1996; Koda 2001; Shibata 2002; Lencioni 2003; Gan 2004; Chen
2005; Lin 2005; Shiina 2005; Aikata 2006).
All the trials were at low risk of other bias.
Effects of interventions
See: Summary of findings for the main comparison Surgery
versus radiofrequency ablation for people with early- or very
early-stage hepatocellular carcinoma; Summary of findings 2
Percutaneous alcohol injection versus radiofrequency ablation for
people with early- or very early-stage hepatocellular carcinoma;
Summary of findings 3 Laser ablation versus radiofrequency
ablation for people with early- or very early-stage hepatocellular
carcinoma; Summary of findings 4 Transarterial embolisation
plus radiofrequency ablation versus radiofrequency ablation
for people with early- or very early-stage hepatocellular
carcinoma; Summary of findings 5 Transarterial embolisation
plus percutaneous alcohol injection versus percutaneous alcohol
injection for people with early- or very early-stage hepatocellular
carcinoma
Surgery versus radiofrequency ablation
Mortality at maximal follow-up
A total of four trials including 574 participants reported mortality
at maximal follow-up (Chen 2006; Huang 2010; Fang 2014;
Lee 2014). There was no evidence of difference in mortality at
maximal follow-up between the groups (hazard ratio (HR) 0.80,
95% confidence interval (CI) 0.60 to 1.08; 574 participants; 4
trials; I2 = 68) (Analysis 1.1).
Cancer-related mortality at maximal follow-up
One trial including 230 participants reported cancer-related mor-
tality at maximal follow-up (Huang 2010). The cancer-related
mortality was lower in the surgery group (20/115 (17.4%)) than
in the radiofrequency ablation group (43/115 (37.4%)) (odds ra-
tio (OR) 0.35, 95% CI 0.19 to 0.65; 230 participants; 1 trial)
(Analysis 1.2).
Mortality (< 1 year)
None of the trials reported this outcome.
Mortality (> 1 year)
One trial including 230 participants reported mortality (> 1 year)
(Huang 2010). The mortality (> 1 year) was lower in the surgery
group (28/115 (24.3%)) than in the radiofrequency ablation
group (52/115 (45.2%)) (OR 0.39, 95% CI 0.22 to 0.68; 230
participants; 1 trial) (Analysis 1.3).
Serious adverse events (number of participants)
One trial including 120 participants reported serious adverse
events (number of participants) (Fang 2014). The serious adverse
events (number of participants) was higher in the surgery group
(14/60 (23.3%)) than in the radiofrequency ablation group (1/60
(1.7%)) (OR 17.96, 95% CI 2.28 to 141.60; 120 participants; 1
trial) (Analysis 1.4).
Serious adverse events (number of events)
Two trials including 391 participants reported number of serious
adverse events (Chen 2006; Huang 2010). The number of serious
adverse events was higher in the surgery group (adjusted rate: 11.3
events per 100 participants) than in the radiofrequency ablation
group (3/186 (1.6 events per 100 participants)) (rate ratio 7.02,
95%CI2.29 to 21.46; 391 participants; 2 trials; I2 =0%) (Analysis
1.5).
Any adverse events (number of participants)
Two trials including 183 participants reported any adverse events
(number of participants) (Fang 2014; Lee 2014). The adverse
events (number of participants) was higher in the surgery group
than in the radiofrequency ablation group using the fixed-effect
model (OR 3.83, 95% CI 1.70 to 8.60; 183 participants; 2 trials;
I2 = 76%); there was no evidence of difference between the groups
(surgery: adjusted proportion: 35.2% versus radiofrequency abla-
tion: 11/94 (11.7%)) using the random-effects model (OR 4.09,
95% CI 0.61 to 27.41; 183 participants; 2 trials; I2 = 76%) (Anal-
ysis 1.6).
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Any adverse events (number of events)
Two trials including 391 participants reported number of any
adverse events (Chen 2006; Huang 2010). The number of any
adverse events was higher in the surgery group (adjusted rate: 47.5
events per 100 participants) than in the radiofrequency ablation
group (20/186 (10.8 events per 100 participants)) (RR 4.42, 95%
CI 2.74 to 7.15; 391 participants; 2 trials; I2 = 0%) (Analysis 1.7).
Health-related quality of life
None of the trials reported health-related quality of life at any time
point.
Hepatocellular carcinoma recurrence (local or distal)
Three trials including413participants reported hepatocellular car-
cinoma recurrence (local or distal) (Huang 2010; Fang 2014; Lee
2014). The hepatocellular carcinoma recurrence (local or distal)
was lower in the surgery group (adjusted proportion: 41.2%) than
in the radiofrequency ablation group (119/209 (56.9%)) (OR
0.53, 95% CI 0.35 to 0.78; 413 participants; 3 trials; I2 = 36%)
(Analysis 1.8).
Hepatocellular carcinoma recurrence (recurrence in the
liver)
Two trials including 350 participants reported hepatocellular car-
cinoma recurrence (recurrence in liver) (Huang 2010; Fang 2014).
The proportion of people with hepatocellular carcinoma recur-
rence (recurrence in liver) was lower in the surgery group (adjusted
proportion: 29.7%) than in the radiofrequency ablation group
(81/175 (46.3%)) (OR 0.49, 95% CI 0.31 to 0.78; 350 partici-
pants; 2 trials; I2 = 6%) (Analysis 1.9).
Length of hospital stay
Three trials including 530 participants reported the length of hos-
pital stay (Chen 2006; Huang 2010; Fang 2014). The length of
hospital stay was longer in the surgery group than in the radiofre-
quency ablation group (mean difference (MD) 8.42 days, 95%CI
7.84 to 9.01; 530 participants; 3 trials; I2 = 86%) (Analysis 1.10).
Overall summary of comparisons in which there was
some evidence of difference
• Cancer-related mortality was lower in the surgery group
than in the radiofrequency ablation group (OR 0.35, 95% CI
0.19 to 0.65; 230 participants; 1 trial).
• Mortality (> 1 year) was lower in the surgery group than in
the radiofrequency ablation group (OR 0.39, 95% CI 0.22 to
0.68; 230 participants; 1 trial).
• Serious adverse events (number of participants) and
number of serious adverse events was higher in the surgery group
than in the radiofrequency ablation group (OR 17.96, 95% CI
2.28 to 141.60; 120 participants; 1 trial and RR 7.02, 95% CI
2.29 to 21.46; 391 participants; 2 trials; I2 = 0%).
• Number of any adverse events was higher in the surgery
group than in the radiofrequency ablation group (RR 4.42, 95%
CI 2.74 to 7.15; 391 participants; 2 trials; I2 = 0%).
• The proportion of people with hepatocellular carcinoma
recurrence (local or distal) and hepatocellular carcinoma
recurrence (recurrence in liver) was lower in the surgery group
than in the radiofrequency ablation group (OR 0.53, 95% CI
0.35 to 0.78; 413 participants; 3 trials; I2 = 36% and OR 0.49,
95% CI 0.31 to 0.78; 350 participants; 2 trials; I2 = 6%).
• Length of hospital stay was longer in the surgery group than
in the radiofrequency ablation group (MD 8.42 days, 95% CI
7.84 to 9.01; 530 participants; 3 trials; I2 = 86%).
Subgroup analyses
Because of the paucity of data, we did not perform any subgroup
analyses.
Sensitivity analysis
Because of the paucity of data, we did not perform a sensitiv-
ity analysis of imputing information based on different scenarios,
that is it was unclear whether there were any postrandomisation
dropouts in many trials, as well as to which group these postran-
domisation dropouts belonged even when the number of postran-
domisation dropouts was reported. We did not impute standard
deviation, therefore we did not perform a sensitivity analysis to
assess the impact of imputing the standard deviation.
We performed a sensitivity analysis excluding the trial in which
19 participants from the radiofrequency ablation group were ex-
cluded because they underwent surgical resection (Chen 2006).
As it was not possible to perform a sensitivity analysis for the pri-
mary outcome of mortality at maximal follow-up by imputing
the information based on different scenarios (this being a time-to-
event outcome), we performed a post hoc sensitivity analysis by
excluding this trial. Excluding this trial did not alter the conclu-
sions (Analysis 1.11).
Reporting bias
We did not assess reporting bias by creating a funnel plot because
of the few trials included for each comparison.
Using fixed-effect model versus random-effects model
The interpretation of results was not altered based on the model
used for analysis for any of the analyses.
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Trial Sequential Analysis
We performed a Trial Sequential Analysis for all-cause mortality at
maximal follow-up. As shown in Figure 4, the cumulative Z-curves
(blue lines) did not cross any of the trial sequential monitoring
boundaries (red lines). They did not cross the conventional alpha
boundary of 2.5% (green lines) either, suggesting a high risk of
random error.
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Figure 4. Trial Sequential Analysis of all-cause mortality at maximal follow-up for surgery versus
radiofrequency ablation. We used an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk
reduction (RRR) of 20% (upper figure) and that observed in trials (20%) (lower figure), control group
proportion (Pc) observed in the trials (30% mortality in about 2 to 3 years), and I2 of 0% (upper figure) and
that observed in the trials (I2 = 68%) (lower figure). The accrued sample size (574) is only a fraction of the
information size (IS) (3351 trial participants) or heterogeneity-adjusted information size (HIS) (5966 trial
participants). As shown in all the comparisons, the cumulative Z-curves (blue line) do not cross any of the trial
sequential monitoring boundaries (red lines), and neither do they cross the conventional alpha boundary of
2.5% (green line).
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Quality of the evidence
The overall quality of the evidence was low or very low for all out-
comes (Summary of findings for the main comparison). All of the
trials were at high risk of bias. However, for all-cause mortality, the
issue of bias due to blinding does not arise; therefore, we down-
graded the quality of the evidence one level for all-cause mortality
and two levels for the remaining comparisons. There was no issue
of indirectness, as all of the outcomes were clinical outcomes and
only direct comparisons were used. The sample size was small (all
comparisons downgraded one level) and the confidence intervals
overlapped clinically significant effect and clinically insignificant
effect for most comparisons (downgraded one level). In addition,
there was substantial heterogeneity for some of the outcomes, re-
sulting in further downgrading by one level. We did not explore
publication bias because of the few trials included in this review.
Comparison of non-surgical interventions
Mortality at maximal follow-up
Ten trials including 1417 participants reported mortality at max-
imal follow-up (Bolondi 1996; Koda 2001; Lencioni 2003; Chen
2005; Lin 2005; Shiina 2005; Aikata 2006; Brunello 2008;
Giorgio 2011; Costanzo 2015).
Mortality at maximal follow-up was higher in the percutaneous
acetic acid injection group (HR 1.77, 95% CI 1.12 to 2.79; 125
participants; 1 trial) and the percutaneous alcohol injection group
(HR 1.49, 95% CI 1.18 to 1.88; 882 participants; 5 trials; I2
= 57%) than in the radiofrequency ablation group. There was
no evidence of difference in any of the remaining comparisons
(Analysis 2.1).
Cancer-related mortality at maximal follow-up
Five trials including 717 participants reported cancer-related mor-
tality at maximal follow-up across all comparisons (Koda 2001;
Lencioni 2003; Lin 2005; Shiina 2005; Costanzo 2015). Cancer-
related mortality at maximal follow-up was higher in the percuta-
neous alcohol injection group (adjusted proportion: 16.8%) than
in the radiofrequency ablation group (20/232 (8.6%)) (OR 2.18,
95% CI 1.22 to 3.89; 458 participants; 3 trials; I2 = 0%). There
was no evidence of difference in any of the remaining comparisons
(Analysis 2.2).
Mortality (< 1 year)
Two trials including 74 participants reported mortality (< 1 year)
(El Kady 2013; Orlacchio 2014). There were no deaths within
one year in either trial.
Mortality (> 1 year)
Six trials including 852 participants reported mortality (> 1 year)
across all comparisons (Koda 2001; Lencioni 2003; Lin 2005;
Shiina 2005; Brunello 2008; Costanzo 2015).Mortality (> 1 year)
was higher in the percutaneous alcohol injection group (adjusted
proportion: 29.7%) than in the radiofrequency ablation group
(62/302 (20.5%)) (OR 1.69, 95% CI 1.15 to 2.49; 598 partici-
pants; 4 trials; I2 = 0%). There was no evidence of difference in
any of the remaining comparisons (Analysis 2.3).
Serious adverse events (number of participants)
Eleven trials including 934 participants reported serious adverse
events (number of participants) across all comparisons (Koda
2001; Shibata 2002; Lencioni 2003; Gan 2004; Chen 2005; Lin
2005; Aikata 2006; Brunello 2008; El Kady 2013; Orlacchio
2014; Costanzo 2015). There was no evidence of difference in any
of the comparisons (Analysis 2.4).
Serious adverse events (number of events)
Two trials including 278 participants reported number of serious
adverse events across all comparisons (Shiina 2005; Aikata 2006).
There was no evidence of difference in any of the comparisons
(Analysis 2.5).
Any adverse events (number of participants)
Three trials including 611 participants reported any adverse
events (number of participants) across all comparisons (Lin 2005;
Brunello 2008; Giorgio 2011). There was no evidence of differ-
ence in any of the comparisons (Analysis 2.6).
Any adverse events (number of events)
Six trials including 732 participants reported number of any ad-
verse events across all comparisons (Koda 2001; Lencioni 2003;
Shiina 2005; ElKady 2013;Orlacchio 2014; Costanzo 2015). The
number of any adverse events was lower in the TACE plus percu-
taneous alcohol injection group (adjusted rate: 438.5 events per
100 participants) than in the percutaneous alcohol injection group
(215/26 (826.9 events per 100 participants)) (RR 0.53, 95% CI
0.42 to 0.67; 52 participants; 1 trial). There was no evidence of
difference in any of the remaining comparisons (Analysis 2.7).
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Health-related quality of life
None of the trials reported this outcome.
Hepatocellular carcinoma recurrence (local or distal)
Three trials including511participants reported hepatocellular car-
cinoma recurrence (local or distal) across all comparisons (Shiina
2005; Brunello 2008; Costanzo 2015). The proportion of peo-
ple with hepatocellular carcinoma recurrence (local or distal) was
higher in the percutaneous alcohol injection group (adjusted pro-
portion: 68.3%) than in the radiofrequency ablation group (110/
188 (58.5%)) (OR 1.58, 95% CI 1.02 to 2.45; 371 participants;
2 trials; I2 = 0%). There was no evidence of difference in any of
the remaining comparisons (Analysis 2.8).
Hepatocellular carcinoma recurrence (recurrence in liver)
Four trials including 439 participants reported hepatocellular car-
cinoma recurrence (recurrence in liver) across all comparisons
(Gan 2004; Shiina 2005; El Kady 2013; Costanzo 2015). There
was no evidence of difference in any of the comparisons (Analysis
2.9).
Length of hospital stay
One trial including232participants reported the length of hospital
stay across all comparisons (Shiina 2005). The length of hospital
stay was longer in the percutaneous alcohol injection group than
in the radiofrequency ablation group in this trial (MD 15.30 days,
95% CI 13.23 to 17.37; 232 participants; 1 trial).
Overall summary of comparisons in which there was
some evidence of difference
• Mortality at maximal follow-up was higher in the
percutaneous acetic acid injection group (HR 1.77, 95% CI 1.12
to 2.79; 125 participants; 1 trial) and the percutaneous alcohol
injection group (HR 1.49, 95% CI 1.18 to 1.88; 882
participants; 5 trials; I2 = 57%) than in the radiofrequency
ablation group.
• Cancer-related mortality at maximal follow-up was higher
in the percutaneous alcohol injection group than in the
radiofrequency ablation group (OR 2.18, 95% CI 1.22 to 3.89;
458 participants; 3 trials; I2 = 0%).
• Mortality (> 1 year) was higher in the percutaneous alcohol
injection group than in the radiofrequency ablation group (OR
1.69, 95% CI 1.15 to 2.49; 598 participants; 4 trials; I2 = 0%).
• Number of any adverse events was lower in the TACE plus
percutaneous alcohol injection group than the percutaneous
alcohol injection group (RR 0.53, 95% CI 0.42 to 0.67; 52
participants; 1 trial).
• The proportion of people with hepatocellular carcinoma
recurrence (local or distal) was higher in the percutaneous alcohol
injection group than in the radiofrequency ablation group (OR
1.58, 95% CI 1.02 to 2.45; 371 participants; 2 trials; I2 = 0%).
• Length of hospital stay was longer in the percutaneous
alcohol injection group than in the radiofrequency ablation
group (MD 15.30 days, 95% CI 13.23 to 17.37; 232
participants; 1 trial).
Subgroup analyses
Because of the paucity of data, we did not perform any subgroup
analyses.
Sensitivity analysis
Because of the paucity of data, we did not perform a sensitivity
analysis of imputing information based on different scenarios, and
we did not perform a sensitivity analysis to assess the impact of
imputing the standard deviation.
Reporting bias
We did not assess reporting bias by creating a funnel plot because
of the few trials included for each comparison.
Using fixed-effect model versus random-effects model
The interpretation of results was not altered based on the model
used for analysis.
Trial Sequential Analysis
The required sample size for identifying a 20% relative risk reduc-
tion in the different outcomes based on an alpha error of 5%, a
beta error of 20%, and the control group (radiofrequency abla-
tion) proportion observed across all trials were as follows.
• Cancer-related mortality at maximal follow-up (control
group proportion: 9.6%): 6722 people
• Mortality < 1 year (control group proportion: 0%): not
estimable
• Mortality > 1 year (control group proportion: 21.5%):
2648 people
• Serious adverse events (proportion) (control group
proportion: 2.0%): 34,688 people
• Adverse events (proportion) (control group proportion:
6.6%): 10,066 people
• Hepatocellular carcinoma recurrence (local or distal)
(control group proportion: 60.5%): 530 people
• Hepatocellular carcinoma recurrence (liver) (control group
proportion: 49.5%): 790 people
The above mentioned are sample sizes uncorrected for heterogene-
ity. In the presence of heterogeneity of 25%, for example, the re-
quired information size for cancer-related mortality at maximal
follow-up is 6772/(1 - 0.25) = 8963 people.
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As seen in the various analyses, only a small fraction of the above
sample sizes has been reached in the comparisons in which there
was no evidence of difference, therefore one cannot rule out alpha
and beta errors in any of these comparisons.
We performed a Trial Sequential Analysis for all-cause mortality at
maximal follow-up for various comparisons. As shown in Figure
5 and Figure 6, the cumulative Z-curves (blue lines) did not cross
any of the trial sequential monitoring boundaries (red lines) for
any of the comparisons. They did not cross the conventional alpha
boundary of 2.5% (green lines) either, suggesting a high risk of
random error.
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Figure 5. Trial Sequential Analysis of all-cause mortality at maximal follow-up for percutaneous alcohol
injection versus radiofrequency ablation. We used an alpha error of 2.5%, power of 90% (beta error of 10%), a
relative risk reduction (RRR) of 20% (upper figure) and that observed in trials (49%) (lower figure), control
group proportion observed in the trials (Pc = 30% mortality in about 2 to 3 years), and heterogeneity of 0%
(upper figure) and that observed in the trials (I2 = 57%) (lower figure). The accrued sample size (882 trial
participants) is only a fraction of the information size (IS) (3351) or heterogeneity-adjusted information size
(HIS) (970 trial participants). As shown in all the comparisons, the cumulative Z-curves (blue line) do not cross
any of the trial sequential monitoring boundaries (red lines), and neither do they cross the conventional alpha
boundary of 2.5% (green line).
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Figure 6. Trial Sequential Analysis of all-cause mortality at maximal follow-up for transarterial
chemoembolisation (TACE) versus percutaneous alcohol injection (PAI) versus PAI. We used an alpha error of
2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20% (upper figure) and that observed
in trials (lower figure), control group proportion observed in the trials (30% mortality in about 2 to 3 years),
and heterogeneity of 0% (upper figure) and that observed in the trials (I2 = 75%) (lower figure). The accrued
sample size (202 trial participants) is only a fraction of the information size (IS) (3351) or heterogeneity-
adjusted information size (HIS) (13,240 trial participants). As shown in all the comparisons, the cumulative Z-
curves (blue line) do not cross any of the trial sequential monitoring boundaries (red lines). They crossed the
conventional alpha boundary of 2.5% (green line).
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Quality of the evidence
As for the surgery versus radiofrequency ablation comparison, the
overall quality of the evidence was also low or very low for all out-
comes for the comparison of non-surgical interventions (Summary
of findings 2; Summary of findings 3; Summary of findings 4;
Summary of findings 5). All of the trials were at high risk of bias.
As before, we downgraded the quality of the evidence one level
for all-cause mortality and two levels for the remaining compar-
isons for risk of bias; one level for imprecision because of small
sample size (all comparisons); one level for imprecision because
the confidence intervals overlapped clinically significant effect and
clinically insignificant effect for most comparisons; and one level
for comparisons with substantial heterogeneity.
27Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Percutaneous alcohol inject ion versus radiof requency ablat ion for people with early- or very early-stage hepatocellular carcinoma
Patient or population: people with early- or very early-stage hepatocellular carcinoma ineligible for surgery
Settings: secondary or tert iary care
Intervention: percutaneous alcohol inject ion
Control: radiof requency ablat ion
Outcomes Illustrative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Radiofrequency ablation Percutaneous alcohol in-
jection
M ortality at maximal fol-
low-up
Follow-up: 23 months to 37
months
300 per 1000 447 per 1000
(354 to 564)
HR 1.49
(1.18 to 1.88)
882
(5 trials)
⊕©©©
very low1,2,3
Cancer- related mortality at
maximal follow-up
Follow-up: 23 months to 37
months
96 per 1000 188 per 1000
(115 to 292)
OR 2.18
(1.22 to 3.89)
458
(3 trials)
⊕⊕©©
low1,2
Serious adverse events
(number of participants)
Follow-up: 23 months to 36
months
20 per 1000 13 per 1000
(4 to 47)
OR 0.67
(0.19 to 2.40)
365
(3 trials)
⊕©©©
very low1,2,3
Serious adverse events
(number of events)
Follow-up: 37 months
34 per 1000 26 per 1000
(6 to 118)
Rate ratio 0.78
(0.17 to 3.47)
232
(1 trial)
⊕©©©
very low1,2,3
Health- related quality of
life
None of the trials reported this outcome.
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* The basis for the assumed risk f or all-cause mortality is the approximate control group proport ions at two to three years reported in the Kaplan-Meier curves in the trials that
reported mortality at maximal-follow-up. We have assumed proport ional hazards. The basis for the assumed risk f or other outcomes is based on the mean control group
proport ion. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; HR: hazard rat io; OR: odds rat io; RR: rate rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded one level because of within-study risk of bias: there was unclear or high risk of bias in the trial(s).
2Downgraded one level because of imprecision: the sample size was small.
3Downgraded one level because of imprecision: the conf idence intervals overlapped clinically signif icant ef fect and clinically
insignif icant ef fect.
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Laser ablat ion versus radiof requency ablat ion for people with early- or very early-stage hepatocellular carcinoma
Patient or population: people with early- or very early-stage hepatocellular carcinoma ineligible for surgery
Settings: secondary or tert iary care
Intervention: laser ablat ion
Control: radiof requency ablat ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Radiofrequency ablation Laser ablation
M ortality at maximal fol-
low-up
Follow-up: not stated
300 per 1000 468 per 1000
(262 to 731)
HR 1.77
(0.85 to 3.68)
140
(1 trial)
⊕©©©
very low1,2,3
Cancer- related mortality at
maximal follow-up
Follow-up: not stated
96 per 1000 118 per 1000
(49 to 258)
OR 1.26
(0.49 to 3.27)
140
(1 trial)
⊕©©©
very low1,2,3
Serious adverse events
(number of participants)
Follow-up: 12 months in 1
trial and not stated in an-
other trial
20 per 1000 20 per 1000
(1 to 250)
OR 1.00
(0.06 to 16.31)
170
(2 trials)
⊕©©©
very low1,2,3
Serious adverse events
(number of events)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
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* The basis for the assumed risk f or all-cause mortality is the approximate control group proport ions at two to three years reported in the Kaplan-Meier curves in the trials that
reported mortality at maximal-follow-up. We have assumed proport ional hazards. The basis for the assumed risk f or other outcomes is based on the mean control group
proport ion. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; HR: hazard rat io; OR: odds rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded one level because of within-study risk of bias: there was unclear or high risk of bias in the trial(s).
2Downgraded one level because of imprecision: the sample size was small.
3Downgraded one level because of imprecision: the conf idence intervals overlapped clinically signif icant ef fect and clinically
insignif icant ef fect.
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Transarterial embolisat ion plus radiof requency ablat ion versus radiof requency ablat ion for people with early- or very early-stage hepatocellular carcinoma
Patient or population: people with early- or very early-stage hepatocellular carcinoma ineligible for surgery
Settings: secondary or tert iary care
Intervention: t ransarterial embolisat ion plus radiof requency ablat ion
Control: radiof requency ablat ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Radiofrequency ablation Transarterial embolisation
plus radiofrequency abla-
tion
M ortality at maximal fol-
low-up
Follow-up: not stated
300 per 1000 329 per 1000
(157 to 602)
HR 1.12
(0.48 to 2.58)
44
(1 trial)
⊕©©©
very low1,2,3
Cancer- related mortality at
maximal follow-up
None of the trials reported this outcome.
Serious adverse events
(number of participants)
Follow-up: 6 months in 1
trial and not stated in an-
other trial
20 per 1000 41 per 1000
(4 to 341)
OR 2.11
(0.18 to 25.35)
84
(2 trials)
⊕©©©
very low1,2,3
Serious adverse events
(number of events)
Follow-up: not stated
There were no events in either group. 44
(1 trial)
⊕©©©
very low1,2,3
Health- related quality of
life
None of the trials reported this outcome.
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* The basis for the assumed risk f or all-cause mortality is the approximate control group proport ions at two to three years reported in the Kaplan-Meier curves in the trials that
reported mortality at maximal-follow-up. We have assumed proport ional hazards. The basis for the assumed risk f or other outcomes is based on the mean control group
proport ion. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; HR: hazard rat io; OR: odds rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded one level because of within-study risk of bias: there was unclear or high risk of bias in the trial(s).
2Downgraded one level because of imprecision: the sample size was small.
3Downgraded one level because of imprecision: the conf idence intervals overlapped clinically signif icant ef fect and clinically
insignif icant ef fect.
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Transarterial embolisat ion plus percutaneous alcohol inject ion versus percutaneous alcohol inject ion for people with early- or very early-stage hepatocellular carcinoma
Patient or population: people with early- or very early-stage hepatocellular carcinoma ineligible for surgery
Settings: secondary or tert iary care
Intervention: t ransarterial embolisat ion plus percutaneous alcohol inject ion
Control: percutaneous alcohol inject ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Percutaneous alcohol in-
jection
Transarterial embolisation
plus percutaneous alcohol
injection
M ortality at maximal fol-
low-up
Follow-up: 19 months to 30
months
300 per 1000 251 per 1000
(207 to 302)
HR 0.81
(0.65 to 1.01)
202
(2 trials)
⊕©©©
very low1,2,3,4
Cancer- related mortality at
maximal follow-up
Follow-up: 30 months
192 per 1000 16 per 1000
(0 to 251)
OR 0.07
(0.00 to 1.41)
52
(1 trial)
⊕©©©
very low1,2,3
Serious adverse events
(number of participants)
Follow-up: 30 months
1 per 1000 5 per 1000
(0 to 106)
OR 5.41
(0.25 to 118.34)
52
(1 trial)
⊕©©©
very low1,2,3
Serious adverse events
(number of events)
None of the trials reported this outcome.
Health- related quality of
life
None of the trials reported this outcome.
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* The basis for the assumed risk f or all-cause mortality is the approximate control group proport ions at two to three years reported in the Kaplan-Meier curves in the trials that
reported mortality at maximal-follow-up. We have assumed proport ional hazards. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in
the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; HR: hazard rat io; OR: odds rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded one level because of within-study risk of bias: there was unclear or high risk of bias in the trial(s).
2Downgraded one level because of imprecision: the sample size was small.
3Downgraded one level because of imprecision: the conf idence intervals overlapped clinically signif icant ef fect and clinically
insignif icant ef fect.
4Downgraded one level because of inconsistency: there was substant ial unexplained heterogeneity.
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D I S C U S S I O N
Summary of main results
We included a total of 18 trials in this review. Four trials (593
participants; 574 participants included for one or more analy-
ses) compared surgery versus radiofrequency ablation in people
with early hepatocellular carcinoma who were eligible to undergo
surgery (Chen 2006; Huang 2010; Fang 2014; Lee 2014), while
14 trials (2533 participants; 2494 participants included for various
analyses) compared different non-surgical interventions in people
with early hepatocellular carcinoma who were not eligible to un-
dergo surgery (Bolondi 1996; Koda 2001; Shibata 2002; Lencioni
2003;Gan2004;Chen2005; Lin 2005; Shiina 2005; Aikata 2006;
Brunello 2008; Giorgio 2011; El Kady 2013; Orlacchio 2014;
Costanzo 2015). Non-surgical interventions compared in the tri-
als that included participants not eligible for surgery included ra-
diofrequency ablation, laser ablation, microwave ablation, percu-
taneous acetic acid injection, percutaneous alcohol injection, a
combination of radiofrequency ablation with systemic chemother-
apy, a combination of radiofrequency ablation with percutaneous
alcohol injection, a combination of transarterial chemoembolisa-
tion with percutaneous alcohol injection, and a combination of
transarterial chemoembolisation with radiofrequency ablation.
Surgery versus radiofrequency ablation
There was no evidence of difference in mortality at maximal fol-
low-up between surgery and radiofrequency ablation. Of the out-
comes in which at least two trials were included, the proportion
of people with hepatocellular carcinoma recurrence (local or dis-
tal) and hepatocellular carcinoma recurrence (recurrence in liver)
were lower in the surgery group than in the radiofrequency ab-
lation group (OR 0.53, 95% CI 0.35 to 0.78; 413 participants;
3 trials; I2 = 36% and OR 0.49, 95% CI 0.31 to 0.78; 350 par-
ticipants; 2 trials; I2 = 6%), while the numbers of serious adverse
events and any adverse events were lower in the radiofrequency
ablation group than in the surgery group (RR 7.02, 95% CI 2.29
to 21.46; 391 participants; 2 trials; I2 = 0% and RR 4.42, 95% CI
2.74 to 7.15; 391 participants; 2 trials; I2 = 0%). In addition, the
length of hospital stay was shorter in the radiofrequency ablation
group than in the surgery group (MD 8.42 days, 95% CI 7.84 to
9.01; 530 participants; 3 trials; I2 = 86%). Overall, it appears that
surgery offers lower cancer recurrence but radiofrequency ablation
is less invasive. Clearly, lower cancer recurrence is more important
to most patients than fewer complications or quicker recovery, un-
less the difference in health-related quality of life compensates for
the lower cancer recurrence. As none of the trials reported health-
related quality of life, we are unable to comment on this. In addi-
tion, it should be noted the trial sequential monitoring boundaries
were not crossed for cancer recurrence (Figure 5), indicating that
there is a high risk of random error in these outcomes. Further-
more, it should be noted that lower cancer recurrence by itself does
not mean that the survival is longer, for example patients may be
able to undergo additional treatments after cancer recurrence and
the overall survival may be improved. There was no evidence of
difference in mortality at maximal follow-up between surgery and
radiofrequency ablation. Thismay be due to additional treatments
that people might have received after cancer recurrence, or is more
likely due to the short follow-up period in the trials. The average
follow-up period in the three trials that reported this information
was between 29 months and 42 months (Table 1). However, the
Kaplan-Meier curves in the trials suggest that most deaths occur
beyond three to four years. Trials of longer follow-up and adequate
sample size are needed to determine whether radiofrequency ab-
lation provides equivalent survival in people with early- or very
early-stage hepatocellular carcinoma who are eligible for surgery.
Consequently, there is lot of uncertainty around this issue.
Non-surgical interventions
In people who were not eligible for surgery, mortality at maximal
follow-up was higher in the percutaneous acetic acid injection
group (HR 1.77, 95% CI 1.12 to 2.79; 125 participants; 1 trial)
and the percutaneous alcohol injection group (HR 1.49, 95%
CI 1.18 to 1.88; 882 participants; 5 trials; I2 = 57%) than in
the radiofrequency ablation group. There was no evidence of a
difference in mortality at maximal follow-up for any of the other
comparisons.
Among the remaining outcomes, for the comparisons in which at
least two trials were included, the only outcomes with evidence
of difference were cancer-related mortality at maximal follow-up,
whichwas higher in the percutaneous alcohol injection group than
in the radiofrequency ablation group (OR 2.18, 95% CI 1.22 to
3.89; 458 participants; 3 trials; I2 = 0%); mortality (> 1 year),
whichwas higher in the percutaneous alcohol injection group than
in the radiofrequency ablation group (OR 1.69, 95% CI 1.15 to
2.49; 598 participants; 4 trials; I2 = 0%); and hepatocellular car-
cinoma recurrence (local or distal), which was again higher in the
percutaneous alcohol injection group than in the radiofrequency
ablation group (OR 1.58, 95% CI 1.02 to 2.45; 371 participants;
2 trials; I2 = 0%). Overall, it appears that radiofrequency ablation
provides better cancer control and survival than percutaneous al-
cohol injection. However, it should be noted that there is a high
risk of random error as shown by the Trial Sequential Analysis
(Figure 4).
Because of the risk of bias, short period of follow-up, and small
samples in the trials, resulting inhigh risk of randomerrors, it is not
possible to say with certainty how people with early hepatocellular
carcinoma should be managed.
Overall completeness and applicability of
evidence
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This review included only people with very early- or early-stage
hepatocellular carcinoma, that is BCLC A stage (single tumour or
three tumours of maximum diameter of 3 cm or less, Child-Pugh
status A to B, and performance status 0). This review is therefore
applicable only to people with very early- or early-stage hepato-
cellular carcinoma. The findings of the comparison between sur-
gical resection and radiofrequency ablation are applicable only to
people who are eligible for surgical resection, while the findings of
the comparison between non-surgical interventions are applicable
only to people who are not eligible for surgical resection.
The participants in the trials included in this review had viral or
non-viral aetiologies and cirrhotic or non-cirrhotic livers. Hence,
the review is applicable to people with viral or non-viral aetiologies
and people with cirrhotic and non-cirrhotic livers. The propor-
tion of people with portal hypertension was not clearly reported
in any of the trials, except Orlacchio 2014, although a proportion
of participants had features suggestive of portal hypertension such
as oesophageal varices or ascites. It therefore appears that the find-
ings of the review are applicable to people with portal hyperten-
sion. The proportion of people who received adjuvant antiviral or
immunotherapy was also not reported, consequently it is unclear
whether the findings of the review are applicable to people who
receive such therapy.
Quality of the evidence
The overall quality of the evidence was low or very low for all
outcomes included in the comparison of surgery versus radiofre-
quency ablation in people who are eligible for surgery and the
comparison of various non-surgical interventions in people who
were not eligible for surgery. All of the trials were at high risk of
bias. As the issue of blinding may not arise for all-cause mortality,
we downgraded the quality of the evidence one level for all-cause
mortality and two levels for the remaining comparisons. Indirect-
ness was not an issue, as all of the outcomes were clinical out-
comes, and only direct comparisons were used. The sample sizes
were small (all comparisons downgraded one level), and the con-
fidence intervals overlapped clinically significant effect and clini-
cally insignificant effect for most comparisons (downgraded one
level). In addition, there was substantial heterogeneity for some of
the outcomes, resulting in further downgrading by one level. We
did not explore publication bias because of the few trials included
in this review; this could have led to one further downgrading.
The average follow-up period in the different trials varied. The
Kaplan-Meier curves in some of the trials that provided this infor-
mation suggest that most deaths occur beyond three to four years
in people with early or very early hepatocellular carcinoma. The
short period of follow-up in the trials and the variability in the
follow-up is another limitation of this review.
Potential biases in the review process
We selected a range of databases and used no language restrictions.
At least two review authors independently selected the trials and
extracted the data, thereby minimising errors. We conducted the
systematic review according to the guidance found in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We included only randomised clinical trials, which provide the
best estimates of treatment effect, in this review. These are the
strengths of the review process.
As discussed in the previous section, the quality of the evidence
was low or very low, which was mainly due to the risk of bias
and sparse data. This is the major limitation of this review. In
addition, we have not included non-randomised studies in this
review. In general, the participants included randomised clinical
trials are carefully selected, while those seen in the clinic have
multiple comorbidities. As a result, the complication rates reported
in this review may be lower than those in actual clinical practice.
Furthermore, it is possible that none of the participants in the
randomised clinical trials developed rare complications because of
the small sample sizes in the trials included in this review.
Randomised clinical trials are known to focus mostly on benefits
and do not collect and report harms in a detailed manner. Accord-
ing to our choice of studies (i.e. only randomised clinical trials),
it is possible that we missed a large number of studies addressing
the reporting of harms. Accordingly, this review is biased towards
benefits ignoring harms. We did not search for interventions and
trials registered at regulatory authorities (e.g. US Food and Drug
Administration andEuropeanMedicines Agency, etc.), whichmay
have resulted in us overlooking trials. As such trials are usually
unpublished, the lack of inclusion of such trials could make our
comparisons look more advantageous than they really are.
We planned to perform a network meta-analysis. However, it was
not possible to assess whether the potential effect modifiers were
similar across different comparisons, and performing a network
meta-analysis in this scenario can be misleading. We therefore did
not perform the network meta-analysis, and instead assessed the
comparative benefits and harms of different interventions using
standard Cochrane methodology.
Agreements and disagreements with other
studies or reviews
There has been one network meta-analysis, Lan 2016, and several
systematic reviews comparing the different interventions included
in this topic (Liu 2010; Zhou 2010; Xu 2012b; Shen 2013; Dong
2014; Fu 2014; Qi 2014; Yi 2014; He 2016). We disagree with
the network meta-analysis that the combination therapy of TACE
and radiofrequency ablation is themost effective strategy for early-
stage hepatocellular carcinoma (Lan 2016), because the compari-
son of TACE and radiofrequency ablation versus radiofrequency
ablation alone was based on two small trials at high risk of bias
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(Aikata 2006; El Kady 2013), and only one of these trials reported
mortality at maximal follow-up (Aikata 2006). We are unable to
comment on the findings of Weis 2015 on comparisons between
percutaneous acetic acid injection and percutaneous alcohol injec-
tion because we were unable to obtain the data for the participants
who met early-stage hepatocellular carcinoma according to BCLC
criteria (it should be noted that many authors defined hepatocel-
lular carcinoma as early despite not meeting the BCLC 0 or BCLC
A criteria). We also disagree with the authors who concluded that
surgery was better than radiofrequency ablation in people with
early-stage hepatocellular carcinoma (Liu 2010; Zhou 2010; Xu
2012b; Dong 2014; Qi 2014; Yi 2014; He 2016). We agree with
the authors who concluded that radiofrequency ablation was bet-
ter than percutaneous ablation in people with early-stage hepa-
tocellular carcinoma (Shen 2013), although some uncertainty re-
mains around this issue. The possible reasons for the differences
in conclusions from other studies include restricting trials to ran-
domised clinical trials only and taking the risk of random errors,
systematic errors, and heterogeneity into account while arriving at
conclusions.
We agree with Fu 2014 that further trials on surgery versus ra-
diofrequency ablation are required to determine the relative ben-
efits and harms of surgery and radiofrequency ablation.
Several systematic reviews also exist in other patient groups of hep-
atocellular carcinoma. Oliveri 2011 found there was no evidence
to support or refute TACE or TAE in people with unresectable
hepatocellular carcinoma. We agree that there is insufficient evi-
dence to support or refute one treatment over the other. However,
we disagree with Weis 2013 that surgery offered better survival
than radiofrequency ablation. The difference in conclusions may
be due to two additional trials that we included in this review. We
are unable to comment on the findings of Abdel-Rahman 2016
on the role of radioembolisation in people with unresectable hep-
atocellular carcinoma because the trials included in this review did
not belong to early stage.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence was of low or very low quality. In people who are
eligible for surgery, there was no evidence of difference in all-
cause mortality at maximal follow-up between surgery and ra-
diofrequency ablation. In people who are not eligible for surgery,
all-cause mortality at maximal follow-up was higher with percu-
taneous acetic acid injection and percutaneous alcohol injection
than with radiofrequency ablation. There was no evidence of dif-
ference in all-cause mortality at maximal follow-up in other com-
parisons.
Implications for research
High-quality randomised clinical trials designed to measure clin-
ically important differences in all-cause mortality and following
the SPIRIT (Standard Protocol Items: Recommendations for In-
terventional Trials), Chan 2013b, and CONSORT guidelines,
Schulz 2010, are needed. Future trials on early hepatocellular car-
cinoma should follow up participants for at least four to five years
because most deaths occur beyond three years. They should also
include other patient-oriented outcomes such as health-related
quality of life.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aikata 2006
Methods Randomised clinical trial
Participants Country: Japan
Number randomised: 44
Postrandomisation dropouts: not stated
Revised sample size: 44
Average age: not stated
Females: not stated
Cirrhosis: not stated
Very early HCC: not stated
Portal hypertension: not stated
Viral aetiology: not stated
Immunotherapy/antiviral adjuvant therapy: not stated
Average follow-up period in months (for all groups): not stated
Criteria for early or very early HCC and other inclusion criteria:
• < 3 cm solitary hypervascular nodules
Interventions Participants were randomly assigned to 2 groups:
Group 1: TACE plus radiofrequency ablation (n = 21).
Further details: cisplatinum TACE, internally cooled electrode (brand not stated) for
radiofrequency ablation.
Group 2: Radiofrequency ablation (n = 23).
Further details: internally cooled electrode (brand not stated)
Outcomes The outcomes reported were:
• mortality,
• adverse events.
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
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Aikata 2006 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: important clinical outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias noted.
Bolondi 1996
Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 150
Postrandomisation dropouts: not stated
Revised sample size: 150
Average age: not stated
Females: not stated
Cirrhosis: 150 (100%)
Very early HCC: not stated
Portal hypertension: not stated
Viral aetiology: not stated
Immunotherapy/antiviral adjuvant therapy: not stated
Average follow-up period in months (for all groups): mean: 19 months
Criteria for early or very early HCC and other inclusion criteria:
• < 5 cm unifocal lesions
Interventions Participants were randomly assigned to 2 groups:
Group 1: PEI plus TACE (n = 66).
Further details not available for TACE or PEI.
Group 2: PEI (n = 84).
Further details not available.
Outcomes The outcomes reported were: mortality.
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
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Bolondi 1996 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: important clinical outcomes expected to bemea-
sured in such trials were not reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias noted.
Brunello 2008
Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 139
Postrandomisation dropouts: 0 (0%)
Revised sample size: 139
Average age: 70 years
Females: 47 (33.8%)
Cirrhosis: 139 (100%)
Very early HCC: not stated
Portal hypertension: not stated
Viral aetiology: 114 (82%)
Immunotherapy/antiviral adjuvant therapy: not stated
Average follow-up period in months (for all groups): all participants: 36 months
Criteria for early or very early HCC and other inclusion criteria:
• 1 to 3 nodules, < 3 cm diameter
• Child-Pugh class A or B
Exclusion criteria:
• Hypovascular HCC
• Lesions not detectable by ultrasound
• Lesions close to the gallbladder, hilum of liver, colon, or stomach
• Venous invasion
• Metastatic disease
• Liver transplantation
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Brunello 2008 (Continued)
Interventions Participants were randomly assigned to 2 groups:
Group 1: PEI (n = 69).
Further details: 2 to 20 mL ethanol (95%).
Group 2: radiofrequency ablation (n = 70).
Further details: Cool-tip or StarBurst system for radiofrequency ablation
Outcomes The outcomes reported were:
• mortality,
• adverse events,
• HCC recurrence.
Notes Authors provided additional information in February 2017.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computerized random generator”
Allocation concealment (selection bias) Low risk Quote: “closed, sequentially numbered envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “the healthcare providers were blinded until the
opening of the sealed envelopes containing the assignation
from the randomized list. The same for the patients, who
were informed about their treatment (PEI or RF) after the
opening of the envelope and were thereafter scheduled for
the appropriate treatment” (author replies)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: after treatment, evaluations of computed tomog-
raphy by a “blinded” observer were considered not feasible
because of different radiological signs produced by the 2
techniques
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: important clinical outcomes were reported.
For-profit bias Low risk Quote: “The work of Eva Pagano was supported by the
Compagnia di San Paolo.”
Other bias Low risk Comment: no other bias noted.
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Chen 2005
Methods Randomised clinical trial
Participants Country: China
Number randomised: 86
Postrandomisation dropouts: not stated
Revised sample size: 86
Average age: 49 years
Females: 13 (15.1%)
Cirrhosis: not stated
Very early HCC: not stated
Portal hypertension: not stated
Viral aetiology: not stated
Immunotherapy/antiviral adjuvant therapy: not stated
Average follow-up period in months (for all groups): not stated
Criteria for early or very early HCC and other inclusion criteria:
• Single nodule < 5 cm
Interventions Participants were randomly assigned to 2 groups:
Group 1: radiofrequency ablation plus PEI (n = 45).
Further details: radiofrequency ablation using RF 2000 (RadioTherapeutics), PEI with
absolute alcohol: volume 1 to 2 times the tumour diameter.
Group 2: radiofrequency ablation (n = 41).
Further details: radiofrequency ablation using RF 2000 (RadioTherapeutics)
Outcomes The outcomes reported were:
• mortality,
• adverse events.
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
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Chen 2005 (Continued)
Selective reporting (reporting bias) Low risk Comment: important clinical outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias noted.
Chen 2006
Methods Randomised clinical trial
Participants Country: China
Number randomised: 180
Postrandomisation dropouts: 19 (10.6%)
Revised sample size: 180
Average age: 51 years
Females: 30 (16.7%)
Cirrhosis: not stated
Very early HCC: not stated
Portal hypertension: not stated
Viral aetiology: not stated
Immunotherapy/antiviral adjuvant therapy: not stated
Average follow-up period in months (for all groups): mean: 29 months
Criteria for early or very early HCC and other inclusion criteria:
• Single nodule < 5 cm
• No vascular involvement
• No extrahepatic metastases
• Child-Pugh class A
Interventions Participants were randomly assigned to 2 groups:
Group 1: surgery (n = 90).
Further details: open surgical resection.
Group 2: radiofrequency ablation (n = 71).
Further details: radiofrequency ablation using RF 2000 or LeVeen (RadioTherapeutics)
Outcomes The outcomes reported were:
• mortality,
• adverse events,
• length of hospital stay.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was done by using random num-
bers generated from a computer in a central registry for this
study”
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Chen 2006 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: important clinical outcomes were reported.
For-profit bias Low risk Quote: “Supported by the grant of Sciences and Technology
Committee of Guangdo Province, China, 2002.”
Other bias Low risk Comment: no other bias noted.
Costanzo 2015
Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 140
Postrandomisation dropouts: 0 (0%)
Revised sample size: 140
Average age: 70 years
Females: 40 (28.6%)
Cirrhosis: 140 (100%)
Very early HCC: not stated
Portal hypertension: not stated
Viral aetiology: not stated
Immunotherapy/antiviral adjuvant therapy: not stated
Average follow-up period in months (for all groups): not stated
Criteria for early or very early HCC and other inclusion criteria:
• Milan criteria
• Child A or B
• No vascular invasion
• No distant metastases
Interventions Participants were randomly assigned to 2 groups:
Group 1: laser (n = 70).
Further details: laser: EchoLaser, Elesta s.r.l.
Group 2: radiofrequency ablation (n = 70).
Further details: radiofrequency ablation: Cool-tip, Valleylab
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Costanzo 2015 (Continued)
Outcomes The outcomes reported were:
• mortality,
• cancer-related mortality,
• adverse events,
• HCC recurrence.
Notes Authors provided additional information in February 2017.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-generated random numbers”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: blinding of participants and personnel was not
performed (author replies)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: blinding of outcome assessors was not performed
(author replies)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: important clinical outcomes were reported.
For-profit bias Low risk Comment: no special source of funding (author replies)
Other bias Low risk Comment: no other bias noted.
El Kady 2013
Methods Randomised clinical trial
Participants Country: Egypt
Number randomised: 40
Postrandomisation dropouts: 0 (0%)
Revised sample size: 40
Average age: 52 years
Females: 11 (27.5%)
Cirrhosis: not stated
Very early HCC: 0 (0%)
Portal hypertension: not stated
Viral aetiology: not stated
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El Kady 2013 (Continued)
Immunotherapy/antiviral adjuvant therapy: not stated
Average follow-up period in months (for all groups): 6
Criteria for early or very early HCC and other inclusion criteria:
• Single nodule > 3 cm
• No portal vein involvement
• No extrahepatic metastasis
Interventions Participants were randomly assigned to 2 groups:
Group 1: TACE plus radiofrequency ablation (n = 20).
Further details: TACEusing 50mgof adriamycin or cisplatin and 10mLof ethiodised oil
(Lipiodol), radiofrequency ablation with RITA 1500X RF generator and RITA StarBurst
XL(RITA Medical Systems, Mountain View, CA, USA).
Group 2: radiofrequency ablation (n = 20).
Further details: radiofrequency ablation with RITA 1500X RF generator and RITA
StarBurst XL(RITA Medical Systems, Mountain View, CA, USA)
Outcomes The outcomes reported were:
• mortality,
• adverse events,
• HCC recurrence.
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomized (computer-based ran-
domization) into two groups”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “After assigning the patients to the groups there were
no drop-outs, as the patient was assigned and managed on
the same day” (author replies)
Selective reporting (reporting bias) Low risk Comment: important clinical outcomes were reported.
For-profit bias Low risk Quote: “The conduct of the research (collection, analysis,
and interpretation of data) and preparation of the article
were totally funded by the authors”
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El Kady 2013 (Continued)
Other bias Low risk Comment: no other bias noted.
Fang 2014
Methods Randomised clinical trial
Participants Country: China
Number randomised: 120
Postrandomisation dropouts: not stated
Revised sample size: 120
Average age: 53 years
Females: 32 (26.7%)
Cirrhosis: 101 (84.2%)
Very early HCC: not stated
Portal hypertension: not stated
Viral aetiology: 107 (89.2%)
Immunotherapy/antiviral adjuvant therapy: not stated
Average follow-up period in months (for all groups): mean: 40 months
Criteria for early or very early HCC and other inclusion criteria:
• ≤ 3 lesions, ≤ 3 cm
• Child-Pugh class A or B
• No vascular invasion
• No distant metastases
• No clinically significant portal hypertension
Interventions Participants were randomly assigned to 2 groups:
Group 1: surgery (n = 60).
Further details: surgery, not stated whether open or laparoscopic resection.
Group 2: radiofrequency ablation (n = 60).
Further details: radiofrequency ablation with Tyco radiofrequency ablation device, Val-
leylab
Outcomes The outcomes reported were:
• mortality,
• adverse events,
• HCC recurrence,
• length of hospital stay.
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: important clinical outcomes were reported.
For-profit bias Low risk Quote: “This work was fully supported by grants
from Zhejiang Science and Technology Agency fund-
ing 2010C13025-1 (H.M. Pan), National Natural Sci-
ence Foundation of China 81272593 (H.M. Pan), Zhe-
jiang Provincial Natural Science Foundation of China
LY13H160013 (Y. Fang) and Zhejiang Provincial Natural
Science Foundation of China LQ13H160009 (W. Chen)”
Other bias Low risk Comment: no other bias noted.
Gan 2004
Methods Randomised clinical trial
Participants Country: China
Number randomised: 38
Postrandomisation dropouts: 11 (28.9%)
Revised sample size: 27
Average age: 53 years
Females: 3 (11.1%)
Cirrhosis: not stated
Very early HCC: not stated
Portal hypertension: not stated
Viral aetiology: not stated
Immunotherapy/antiviral adjuvant therapy: not stated
Average follow-up period in months (for all groups): all participants were followed up
for 12 months
Criteria for early or very early HCC and other inclusion criteria:
• 1 to 2 nodules, ≤ 3 cm
• No portal vein involvement
• No distant metastases
• Life expectancy > 3 months
Interventions Participants were randomly assigned to 2 groups:
Group 1: radiofrequency ablation plus systemic chemotherapy (n = 15).
Further details: radiofrequency ablation with RF 2000 (RadioTherapeutics); chemother-
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apy with epirubicin 50 mg, cisplatin 40 mg, and floxuridine 500 mg.
Group 2: radiofrequency ablation (n = 12).
Further details: radiofrequency ablation: RF 2000 (RadioTherapeutics)
Outcomes The outcomes reported were:
• adverse events,
• HCC recurrence.
Notes Reasons for postrandomisation dropouts: follow-up less than 1 year
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: important clinical outcomes expected to bemea-
sured in such trials were not reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias noted.
Giorgio 2011
Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 285
Postrandomisation dropouts: 0 (0%)
Revised sample size: 285
Average age: 70 years
Females: 78 (27.4%)
Cirrhosis: 285 (100%)
Very early HCC: 71 (24.9%)
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Portal hypertension: not stated
Viral aetiology: 285 (100%)
Immunotherapy/antiviral adjuvant therapy: not stated
Average follow-up period in months (for all groups): mean: 37 months
Criteria for early or very early HCC and other inclusion criteria:
• Single nodule, ≤ 3 cm
Interventions Participants were randomly assigned to 2 groups:
Group 1: PEI (n = 143).
Further details: PEI using 4 to 20 mL of 95% ethanol depending upon tumour volume.
Group 2: radiofrequency ablation (n = 142).
Further details: radiofrequency ablation generator details not stated
Outcomes The outcomes reported were:
• mortality,
• adverse events.
Notes Although mortality was reported, this was a severely biased estimate, as 14 people who
could not undergo radiofrequency ablation were excluded. We therefore did not use the
survival information
Authors provided additional information in February 2017.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “random number generator”
Allocation concealment (selection bias) Low risk Quote: “The person randomising the patient were unaware
of what the next treatment allocation was. It was used a cen-
tralised randomisation service to ensuring allocation con-
cealment. So it was not possible for the investigators to know
the allocation sequence in advance” (author replies)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The patients and healthcare providers were not
blinded due to the nature of the treatments used in to the
study (PEI versus RFA)” (author replies)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The outcome assessors were blinded as they did not
know the patient was referring to the results” (author replies)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: important clinical outcomes were reported.
60Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Giorgio 2011 (Continued)
For-profit bias Low risk Quote: “The study was not funded. It was self-financed by
the hospital” (author replies)
Other bias Low risk Comment: no other bias noted.
Huang 2010
Methods Randomised clinical trial
Participants Country: China
Number randomised: 230
Postrandomisation dropouts: 0 (0%)
Revised sample size: 230
Average age: 56 years
Females: 66 (28.7%)
Cirrhosis: 142 (61.7%)
Very early HCC: not stated
Portal hypertension: not stated
Viral aetiology: 215 (93.5%)
Immunotherapy/antiviral adjuvant therapy: not stated
Average follow-up period in months (for all groups): median: 42 months
Criteria for early or very early HCC and other inclusion criteria:
• Milan criteria
• Child A or B
• No vascular invasion
• No distant metastases
Interventions Participants were randomly assigned to 2 groups:
Group 1: surgery (n = 115).
Further details: not stated whether open or laparoscopic resection.
Group 2: radiofrequency ablation (n = 115).
Further details: radiofrequency ablation using Cool-tip (Radionics)
Outcomes The outcomes reported were:
• mortality,
• cancer-related mortality,
• adverse events,
• HCC recurrence,
• length of hospital stay.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomization method with a computer”
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Allocation concealment (selection bias) Low risk Quote: “Physicians received the envelope for each patient
in the registry sequence kept in a container given by the
statistician and kept by the chief nurse of our center.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Because of the nature of the interventions, the dou-
ble-blind technique was not used”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Because of the nature of the interventions, the dou-
ble-blind technique was not used”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: important clinical outcomes were reported.
For-profit bias Low risk Quote: “This study has not received any support from in-
dustry or private corporations.”
Other bias Low risk Comment: no other bias noted.
Koda 2001
Methods Randomised clinical trial
Participants Country: Japan
Number randomised: 52
Postrandomisation dropouts: not stated
Revised sample size: 52
Average age: 66 years
Females: 22 (42.3%)
Cirrhosis: 46 (88.5%)
Very early HCC: not stated
Portal hypertension: not stated
Viral aetiology: 49 (94.2%)
Immunotherapy/antiviral adjuvant therapy: not stated
Average follow-up period in months (for all groups): mean: 30
Criteria for early or very early HCC and other inclusion criteria:
• 1 to 3 nodules, ≤ 3 cm
• No portal thrombosis
• No extrahepatic metastases
Interventions Participants were randomly assigned to 2 groups:
Group 1: TACE plus PEI (n = 26).
Further details: TACE using iodised oil, epirubicin hydrocholoride, and gelatin sponge;
PEI using 1 to 12 mL absolute alcohol per session.
Group 2: PEI (n = 26).
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Further details: PEI using 1 to 12 mL absolute alcohol per session
Outcomes The outcomes reported were:
• mortality,
• cancer-related mortality,
• adverse events.
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Quote: “sealed-envelope method”
Comment: further details were not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: important clinical outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias noted.
Lee 2014
Methods Randomised clinical trial
Participants Country: South Korea
Number randomised: 63
Postrandomisation dropouts: not stated
Revised sample size: 63
Average age: not stated
Females: not stated
Cirrhosis: not stated
Very early HCC: 0 (0%)
Portal hypertension: not stated
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Viral aetiology: not stated
Immunotherapy/antiviral adjuvant therapy: not stated
Average follow-up period in months (for all groups): not stated
Criteria for early or very early HCC and other inclusion criteria:
• Single nodule 2 to 4 cm
Interventions Participants were randomly assigned to 2 groups:
Group 1: surgery (n = 29).
Further details: not stated whether surgery was open or laparoscopic resection.
Group 2: radiofrequency ablation (n = 34).
Further details not available.
Outcomes The outcomes reported were:
• mortality,
• adverse events,
• HCC recurrence.
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: important clinical outcomes were reported.
For-profit bias High risk Comment: grant/research support: Green Cross, Chong
Kun Dang Pharm, Novartis, SK Chemicals
Other bias Low risk Comment: no other bias noted.
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Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 104
Postrandomisation dropouts: 2 (1.9%)
Revised sample size: 102
Average age: 68 years
Females: 36 (35.3%)
Cirrhosis: 102 (100%)
Very early HCC: not stated
Portal hypertension: not stated
Viral aetiology: 82 (80.4%)
Immunotherapy/antiviral adjuvant therapy: not stated
Average follow-up period in months (for all groups): mean: 23 months
Criteria for early or very early HCC and other inclusion criteria:
• Milan criteria
• Child class A or B
• No vascular invasion
• No distant metastases
Interventions Participants were randomly assigned to 2 groups:
Group 1: PEI (n = 50).
Further details: PEI using 2 to 10 mL 95% alcohol per session.
Group 2: radiofrequency ablation (n = 52).
Further details: radiofrequency ablation using 500L RITA Medical Systems
Outcomes The outcomes reported were:
• mortality,
• cancer-related mortality,
• adverse events.
Notes Reasons for postrandomisation dropouts:
1. Tumour size > 5 cm.
2. Extrahepatic cancer identified retrospectively.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-generated randomization list”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: important clinical outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias noted.
Lin 2005
Methods Randomised clinical trial
Participants Country: Taiwan
Number randomised: 187
Postrandomisation dropouts: 0 (0%)
Revised sample size: 187
Average age: 61 years
Females: 66 (35.3%)
Cirrhosis: 187 (100%)
Very early HCC: not stated
Portal hypertension: not stated
Viral aetiology: 184 (98.4%)
Immunotherapy/antiviral adjuvant therapy: not stated
Average follow-up period in months (for all groups): mean: 27 months
Criteria for early or very early HCC and other inclusion criteria:
• 1. 1 to 3 nodules, ≤ 3 cm
• 2. No vascular invasion
• 3. No extrahepatic metastases
• 4. Child Pugh class A or B
Interventions Participants were randomly assigned to 3 groups:
Group 1: radiofrequency ablation (n = 62).
Further details: radiofrequency ablation using RF 2000 (RadioTherapeutics).
Group 2: PEI (n = 62).
Further details: PEI using 2 to 10 mL absolute alcohol per session.
Group 3: percutaneous acetic acid injection (n = 63).
Further details: percutaneous acetic acid injection using 1 to 3 mL 50% acetic acid
Outcomes The outcomes reported were:
• mortality,
• cancer-related mortality,
• adverse events.
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Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer randomisation list”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: important clinical outcomes were reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias noted.
Orlacchio 2014
Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 30
Postrandomisation dropouts: 0 (0%)
Revised sample size: 30
Average age: 72 years
Females: 9 (30%)
Cirrhosis: 30 (100%)
Very early HCC: not stated
Portal hypertension: 30 (100%)
Viral aetiology: 27 (90%)
Immunotherapy/antiviral adjuvant therapy: not stated
Average follow-up period in months (for all groups): all participants were followed up
for 12 months
Criteria for early or very early HCC and other inclusion criteria:
• Single nodule < 4 cm in diameter
• Child-Pugh class A or B
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Interventions Participants were randomly assigned to 2 groups:
Group 1: laser (n = 15).
Further details: laser using EchoLaser XVG system.
Group 2: radiofrequency ablation (n = 15).
Further details: radiofrequency ablation using RF 3000, Boston Scientific Corporation
Outcomes The outcomes reported were:
• mortality,
• adverse events.
Notes Authors provided additional information in February 2017.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomisation software was used to allocate each
patient to a treatment group”
Allocation concealment (selection bias) Unclear risk Quote: “randomisation software was used to allocate each
patient to a treatment group”
Comment: further details were not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: participants and personnel were not blinded
(based on author replies)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: outcome assessors were not blinded (based on
author replies)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: important clinical outcomes were reported.
For-profit bias Low risk Comment: no special source of funding (author replies)
Other bias Low risk Comment: no other bias noted.
Shibata 2002
Methods Randomised clinical trial
Participants Country: Japan
Number randomised: 72
Postrandomisation dropouts: 0 (0%)
Revised sample size: 72
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Average age: 63 years
Females: 22 (30.6%)
Cirrhosis: 72 (100%)
Very early HCC: not stated
Portal hypertension: not stated
Viral aetiology: 71 (98.6%)
Immunotherapy/antiviral adjuvant therapy: not stated
Average follow-up period in months (for all groups): mean: 18 months
Criteria for early or very early HCC and other inclusion criteria:
• 1 to 3 nodules, ≤ 3 cm or single nodule < 4 cm
• No portal thrombosis
• No extrahepatic metastases
Interventions Participants were randomly assigned to 2 groups:
Group 1: microwave ablation (n = 36).
Further details: microwave ablation with Microtaze.
Group 2: radiofrequency ablation (n = 36).
Further details: radiofrequency ablation using RF2000 (Radionics)
Outcomes The outcomes reported were: adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Quote: “sealed-envelope method”
Comment: further details were not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: important clinical outcomes expected to bemea-
sured in such trials were not reported
For-profit bias Unclear risk Comment: this information was not available.
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Other bias Low risk Comment: no other bias noted.
Shiina 2005
Methods Randomised clinical trial
Participants Country: Japan
Number randomised: 232
Postrandomisation dropouts: 0 (0%)
Revised sample size: 232
Average age: not stated
Females: 66 (28.4%)
Cirrhosis: 198 (85.3%)
Very early HCC: not stated
Portal hypertension: not stated
Viral aetiology: 217 (93.5%)
Immunotherapy/antiviral adjuvant therapy: not stated
Average follow-up period in months (for all groups): median: 37 months
Criteria for early or very early HCC and other inclusion criteria:
• 1 to 3 nodules
• No vascular invasion
• No extrahepatic metastases
• Child-Pugh class A or B
Interventions Participants were randomly assigned to 2 groups:
Group 1: PEI (n = 114).
Further details: PEI using 0.5 mL to 1 mL per site (alcohol percentage not stated).
Group 2: radiofrequency ablation (n = 118).
Further details: radiofrequency ablation using CC-1 Cosman Coagulator (Radionics)
Outcomes The outcomes reported were:
• mortality,
• cancer-related mortality,
• adverse events,
• HCC recurrence,
• length of hospital stay.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-generated random numbers”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Double-blind technique was not used because of
the nature of the interventions”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Double-blind technique was not used because of
the nature of the interventions”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: important clinical outcomes were reported.
For-profit bias Unclear risk Quote: “Grants-in-Aid from theMinistry of Education, Sci-
ence, Sports, and Culture of Japan”
Comment: not clear how the remaining part of the study
was funded
Other bias Low risk Comment: no other bias noted.
HCC: hepatocellular carcinoma; PEI: percutaneous ethanol injection; RFA: radiofrequency ablation; TACE: transarterial chemoem-
bolisation; TAE: transarterial embolisation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdelaziz 2014 Not in very early or early hepatocellular carcinoma
Azab 2011 Not in very early or early hepatocellular carcinoma
Casaccia 2015 Not a randomised clinical trial
Chen 2014 Not in very early or early hepatocellular carcinoma
Feng 2012 Not in very early or early hepatocellular carcinoma
Ferrari 2007 Not in very early or early hepatocellular carcinoma
Fukushima 2015 Not in very early or early hepatocellular carcinoma
Gallo 1998 Not in very early or early hepatocellular carcinoma
Goldberg 2002 Not in very early or early hepatocellular carcinoma
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Habib 2002 Not in very early or early hepatocellular carcinoma
Hirakawa 2013 Variations in radiofrequency ablation
Hou 2009 Not in very early or early hepatocellular carcinoma
Huang 2005 Inadequate randomisation (groups were adjusted to equalise numbers)
Huo 2003 Not a randomised clinical trial
Hyun 2016 Not a randomised clinical trial
Kobayashi 2007 Not in very early or early hepatocellular carcinoma
Kuansheng 2011 Not in very early or early hepatocellular carcinoma
Lau 1999 Not in very early or early hepatocellular carcinoma
Lau 2008 Not in very early or early hepatocellular carcinoma
Lin 2004 Not in very early or early hepatocellular carcinoma
Livraghi 1999 Not a randomised clinical trial
Lo 2007 Not in very early or early hepatocellular carcinoma
Lu 2006a In the control group, the ablation was performed with either radiofrequency ablation or microwave ablation
and this was not determined at random
Mizuki 2010 Not in very early or early hepatocellular carcinoma
Muehlbacher 2014 Not in very early or early hepatocellular carcinoma
Ohnishi 1998 Not in very early or early hepatocellular carcinoma
Okusaka 2011 Recurrent hepatocellular carcinoma. Unable to determine disease stage prior to initial treatment
Peng 2012 Recurrent hepatocellular carcinoma. Unable to determine disease stage prior to initial treatment
Pinter 2015 Not in very early or early hepatocellular carcinoma
Shen 2005 Not in very early or early hepatocellular carcinoma
Shibata 2006 Not a randomised clinical trial
Shibata 2009 Not a randomised clinical trial
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Shiozawa 2015 Not a randomised clinical trial
Sun 2016 Not a randomised clinical trial
van Malenstein 2011 Not in very early or early hepatocellular carcinoma
Wu 2015 Variations in surgical resection
Xu 2012a Randomised after resection. Unable to determine disease stage prior to surgery
Xu 2013 Randomised after resection. Unable to determine disease stage prior to initial treatment
Xu 2015 Not in very early or early hepatocellular carcinoma
Yi 2014 In this randomised clinical trial, the decision to perform radiofrequency ablation or microwave ablation was
not random
Yu 2014 Not in very early or early hepatocellular carcinoma
Yu 2016 Not in very early or early hepatocellular carcinoma
Zhang 2002 Not a randomised clinical trial
Zhang 2007 Not in very early or early hepatocellular carcinoma
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D A T A A N D A N A L Y S E S
Comparison 1. Surgery versus radiofrequency ablation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at maximal follow-up 4 574 Hazard Ratio (Fixed, 95% CI) 0.80 [0.60, 1.08]
2 Cancer-related mortality at
maximal follow-up
1 230 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.19, 0.65]
3 Mortality (> 1 year) 1 230 Odds Ratio (M-H, Fixed, 95% CI) 0.39 [0.22, 0.68]
4 Serious adverse events (number
of participants)
1 120 Odds Ratio (M-H, Fixed, 95% CI) 17.96 [2.28, 141.60]
5 Serious adverse events (number
of events)
2 391 Rate Ratio (Fixed, 95% CI) 7.02 [2.29, 21.46]
6 Any adverse events (number of
participants)
2 183 Odds Ratio (M-H, Random, 95% CI) 4.09 [0.61, 27.41]
7 Any adverse events (number of
events)
2 391 Rate Ratio (Fixed, 95% CI) 4.42 [2.74, 7.15]
8 HCC recurrence (local or distal) 3 413 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.35, 0.78]
9 HCC recurrence (recurrence in
liver)
2 350 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.31, 0.78]
10 Length of hospital stay 3 530 Mean Difference (IV, Fixed, 95% CI) 8.42 [7.84, 9.01]
11 Mortality at maximal follow-up
(sensitivity analysis)
3 Hazard Ratio (Fixed, 95% CI) 0.68 [0.47, 1.00]
Comparison 2. Non-surgical interventions
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at maximal follow-up 10 Hazard Ratio (Fixed, 95% CI) Subtotals only
1.1 Laser versus
radiofrequency ablation
1 140 Hazard Ratio (Fixed, 95% CI) 1.77 [0.85, 3.68]
1.2 Percutaneous acetic acid
injection versus radiofrequency
ablation
1 125 Hazard Ratio (Fixed, 95% CI) 1.77 [1.12, 2.79]
1.3 Percutaneous alcohol
injection versus radiofrequency
ablation
5 882 Hazard Ratio (Fixed, 95% CI) 1.49 [1.18, 1.88]
1.4 Radiofrequency ablation
plus percutaneous alcohol
injection versus radiofrequency
ablation
1 86 Hazard Ratio (Fixed, 95% CI) 0.66 [0.41, 1.06]
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1.5 Transarterial
chemoembolisation plus
radiofrequency ablation versus
radiofrequency ablation
1 44 Hazard Ratio (Fixed, 95% CI) 1.12 [0.48, 2.58]
1.6 Percutaneous alcohol
injection versus percutaneous
acetic acid injection
1 125 Hazard Ratio (Fixed, 95% CI) 1.15 [0.79, 1.65]
1.7 Transarterial
chemoembolisation plus
percutaneous alcohol injection
versus percutaneous alcohol
injection
2 202 Hazard Ratio (Fixed, 95% CI) 0.81 [0.65, 1.01]
2 Cancer-related mortality at
maximal follow-up
5 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Laser versus
radiofrequency ablation
1 140 Odds Ratio (M-H, Fixed, 95% CI) 1.26 [0.49, 3.27]
2.2 Percutaneous acetic acid
injection versus radiofrequency
ablation
1 125 Odds Ratio (M-H, Fixed, 95% CI) 2.42 [0.70, 8.31]
2.3 Percutaneous alcohol
injection versus radiofrequency
ablation
3 458 Odds Ratio (M-H, Fixed, 95% CI) 2.18 [1.22, 3.89]
2.4 Percutaneous alcohol
injection versus percutaneous
acetic acid injection
1 125 Odds Ratio (M-H, Fixed, 95% CI) 1.15 [0.43, 3.07]
2.5 Transarterial
chemoembolisation plus
percutaneous alcohol injection
versus percutaneous alcohol
injection
1 52 Odds Ratio (M-H, Fixed, 95% CI) 0.07 [0.00, 1.41]
3 Mortality (> 1 year) 6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Laser versus
radiofrequency ablation
1 140 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.73, 3.12]
3.2 Percutaneous acetic acid
injection versus radiofrequency
ablation
1 124 Odds Ratio (M-H, Fixed, 95% CI) 1.96 [0.82, 4.72]
3.3 Percutaneous alcohol
injection versus radiofrequency
ablation
4 598 Odds Ratio (M-H, Fixed, 95% CI) 1.69 [1.15, 2.49]
3.4 Percutaneous alcohol
injection versus percutaneous
acetic acid injection
1 125 Odds Ratio (M-H, Fixed, 95% CI) 1.21 [0.54, 2.70]
3.5 Transarterial
chemoembolisation plus
percutaneous alcohol injection
versus percutaneous alcohol
injection
1 52 Odds Ratio (M-H, Fixed, 95% CI) 0.41 [0.11, 1.58]
4 Serious adverse events (number
of participants)
11 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Laser versus
radiofrequency ablation
2 170 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 16.31]
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4.2 Microwave ablation versus
radiofrequency ablation
1 72 Odds Ratio (M-H, Fixed, 95% CI) 4.38 [0.46, 41.22]
4.3 Percutaneous acetic acid
injection versus radiofrequency
ablation
1 125 Odds Ratio (M-H, Fixed, 95% CI) 0.13 [0.01, 2.65]
4.4 Percutaneous alcohol
injection versus radiofrequency
ablation
3 365 Odds Ratio (M-H, Fixed, 95% CI) 0.67 [0.19, 2.40]
4.5 Radiofrequency ablation
plus chemotherapy versus
radiofrequency ablation
1 27 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 Radiofrequency ablation
plus percutaneous alcohol
injection versus radiofrequency
ablation
1 86 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.7 Transarterial
chemoembolisation plus
radiofrequency ablation versus
radiofrequency ablation
2 84 Odds Ratio (M-H, Fixed, 95% CI) 2.11 [0.18, 25.35]
4.8 Percutaneous alcohol
injection versus percutaneous
acetic acid injection
1 125 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.9 Transarterial
chemoembolisation plus
percutaneous alcohol injection
versus percutaneous alcohol
injection
1 52 Odds Ratio (M-H, Fixed, 95% CI) 5.41 [0.25, 118.34]
5 Serious adverse events (number
of events)
2 Rate Ratio (Fixed, 95% CI) Totals not selected
5.1 Percutaneous alcohol
injection versus radiofrequency
ablation
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Transarterial
chemoembolisation plus
radiofrequency ablation versus
radiofrequency ablation
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Any adverse events (number of
participants)
3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Percutaneous acetic acid
injection versus radiofrequency
ablation
1 125 Odds Ratio (M-H, Fixed, 95% CI) 0.39 [0.10, 1.59]
6.2 Percutaneous alcohol
injection versus radiofrequency
ablation
3 548 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.43, 1.81]
6.3 Percutaneous alcohol
injection versus percutaneous
acetic acid injection
1 125 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.24]
7 Any adverse events (number of
events)
6 Rate Ratio (Fixed, 95% CI) Subtotals only
7.1 Laser versus
radiofrequency ablation
2 170 Rate Ratio (Fixed, 95% CI) 0.83 [0.57, 1.20]
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7.2 Percutaneous alcohol
injection versus radiofrequency
ablation
2 334 Rate Ratio (Fixed, 95% CI) 0.90 [0.71, 1.14]
7.3 Transarterial
chemoembolisation plus
radiofrequency ablation versus
radiofrequency ablation
1 40 Rate Ratio (Fixed, 95% CI) 1.30 [0.78, 2.14]
7.4 Transarterial
chemoembolisation plus
percutaneous alcohol injection
versus percutaneous alcohol
injection
1 52 Rate Ratio (Fixed, 95% CI) 0.53 [0.42, 0.67]
8 HCC recurrence (local or distal) 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Laser versus
radiofrequency ablation
1 140 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.44, 1.76]
8.2 Percutaneous alcohol
injection versus radiofrequency
ablation
2 371 Odds Ratio (M-H, Fixed, 95% CI) 1.58 [1.02, 2.45]
9 HCC recurrence (recurrence in
liver)
4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 Laser versus
radiofrequency ablation
1 140 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.39, 1.86]
9.2 Percutaneous alcohol
injection versus radiofrequency
ablation
1 232 Odds Ratio (M-H, Fixed, 95% CI) 1.70 [0.96, 3.00]
9.3 Radiofrequency ablation
plus chemotherapy versus
radiofrequency ablation
1 27 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.07, 1.82]
9.4 Transarterial
chemoembolisation plus
radiofrequency ablation versus
radiofrequency ablation
1 40 Odds Ratio (M-H, Fixed, 95% CI) 1.22 [0.35, 4.24]
10 Length of hospital stay 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 Percutaneous alcohol
injection versus radiofrequency
ablation
1 232 Mean Difference (IV, Fixed, 95% CI) 15.3 [13.23, 17.37]
A D D I T I O N A L T A B L E S
Table 1. Characteristics of included studies arranged according to intervention and control
Study name Number of par-
ticipants
randomised
Postrandomisa-
tion dropouts
Number of par-
tici-
pants for whom
outcomewas re-
ported
Intervention(s) Control Average follow-
up period
(months)
In people who were eligible for surgery In people who
for surgery
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Table 1. Characteristics of included studies arranged according to intervention and control (Continued)
Chen 2006 180 19 161 Surgery Radiofrequency
ablation
29
Huang 2010 230 0 230 Surgery Radiofrequency
ablation
42
Fang 2014 120 Not stated 120 Surgery Radiofrequency
ablation
40
Lee 2014 63 Not stated 63 Surgery Radiofrequency
ablation
Not stated
In people who were not eligible for surgery In people who wer
ble for surgery
Bolondi 1996 150 Not stated 150 Percutaneous al-
cohol injec-
tion plus transar-
terial chemoem-
bolisation
Percutaneous al-
cohol injection
19
Koda 2001 52 Not stated 52 Transar-
terial chemoem-
bolisation plus
percutaneous al-
cohol injection
Percutaneous al-
cohol injection
30
Lin 2005 187 0 187 Radiofrequency
ablation
Percutaneous al-
cohol injection,
percuta-
neous acetic acid
injection
27
Orlacchio 2014 30 0 30 Laser Radiofrequency
ablation
12
Costanzo 2015 140 0 140 Laser Radiofrequency
ablation
Not stated
Shibata 2002 72 0 72 Microwave abla-
tion
Radiofrequency
ablation
18
Lencioni 2003 104 2 102 Percutaneous al-
cohol injection
Radiofrequency
ablation
23
Shiina 2005 232 0 232 Percutaneous al-
cohol injection
Radiofrequency
ablation
37
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Table 1. Characteristics of included studies arranged according to intervention and control (Continued)
Brunello 2008 139 0 139 Percutaneous al-
cohol injection
Radiofrequency
ablation
36
Giorgio 2011 285 0 285 Percutaneous al-
cohol injection
Radiofrequency
ablation
37
Gan 2004 38 11 27 Ra-
diofrequency ab-
lation plus che-
motherapy
Radiofrequency
ablation
12
Chen 2005 86 Not stated 86 Ra-
diofrequency ab-
lation plus per-
cutaneous alco-
hol injection
Radiofrequency
ablation
Not stated
Aikata 2006 44 Not stated 44 Transarterial
chemoemboli-
sation plus ra-
diofrequency ab-
lation
Radiofrequency
ablation
Not stated
El Kady 2013 40 0 40 Transarterial
chemoemboli-
sation plus ra-
diofrequency ab-
lation
Radiofrequency
ablation
6
Table 2. Risk of bias in studies arranged according to intervention and control
Study name Random se-
quence gen-
eration
Allo-
cation con-
cealment
Blinding of
partic-
ipants and
health pro-
fessionals
Blinding of
outcome as-
sessors
Incomplete
outcome
data bias
Selective
outcome re-
porting
For-profit
bias
Other bias
In people who were eligible for surgery In people who
for surgery
Chen 2006 Low Unclear Unclear Unclear High Low Low Low
Huang 2010 Unclear Unclear Unclear Unclear Unclear Low Low Low
Fang 2014 Low Low High High Low Low Low Low
Lee 2014 Unclear Unclear Unclear Unclear Unclear Low High Low
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Table 2. Risk of bias in studies arranged according to intervention and control (Continued)
In people who were not eligible for surgery In people who wer
ble for surgery
Bolondi
1996
Unclear Unclear Unclear Unclear Unclear High Unclear Low
Koda 2001 Unclear Unclear Unclear Unclear Unclear Low Unclear Low
Lin 2005 Low Unclear Unclear Unclear Low Low Unclear Low
Orlacchio
2014
Low Unclear High High Low Low Low Low
Costanzo
2015
Low Unclear High High Low Low Low Low
Shibata
2002
Unclear Unclear Unclear Unclear Low High Unclear Low
Lencioni
2003
Low Unclear Unclear Unclear High Low Unclear Low
Shiina 2005 Low Unclear High High Low Low Unclear Low
Brunello
2008
Low Low High High Low Low Low Low
Giorgio
2011
Low Low Unclear Low Low Low Low Low
Gan 2004 Unclear Unclear Unclear Unclear High High Unclear Low
Chen 2005 Unclear Unclear Unclear Unclear Unclear Low Unclear Low
Aikata 2006 Unclear Unclear Unclear Unclear Unclear Low Unclear Low
El Kady
2013
Low Unclear Unclear Unclear Low Low Low Low
80Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
Avik Majumdar, Davide Roccarina, and Kurinchi Gurusamy selected the studies and extracted the data. Avik Majumdar completed
the ’Characteristics of included studies’ and ’Characteristics of excluded studies’ tables. Kurinchi Gurusamy wrote the review. Avik
Majumdar, Davide Roccarina, Emmanuel Tsochatzis, Brian Davidson, and Douglas Thorburn commented critically on the review. All
review authors approved this version before publication.
D E C L A R A T I O N S O F I N T E R E S T
This report is independent research funded by the National Institute for Health Research (NIHR Cochrane Programme Grants, 13/
89/03 - Evidence-based diagnosis and management of upper digestive, hepato-biliary, and pancreatic disorders). The views expressed in
this publication are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR, or the Department
of Health.
Astellas Pharma funded Douglas Thorburn for his attendance at the International Liver Transplantation Society meeting in 2014.
Douglas Thorburn also received GBP 25,000 from Boston Scientific to fund a clinical research fellow in 2013. Emmanuel Tsochatzis
has participated in advisory boards for AstraZeneca and ViiV Healthcare. Avik Majumdar, Davide Roccarina, Kurinchi Gurusamy and
Brian Davidson have no financial disclosures. There are no other financial disclosures to report.
S O U R C E S O F S U P P O R T
Internal sources
• University College London, UK.
External sources
• National Institute for Health Research, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• It was not possible to assess whether the potential effect modifiers were similar across different comparisons, therefore we did not
perform the network meta-analysis and assessed the comparative benefits and harms of different interventions using standard
Cochrane methodology. The methodology that we plan to use if we conduct a network meta-analysis in future is available in
Appendix 3.
• We performed Trial Sequential Analysis in addition to the conventional method of assessing the risk of random errors using P
value.
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N O T E S
Considerable overlap is evident in the Methods section of this review and that of several other reviews written by the same group of
authors.
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